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ABSTRACT 
 
AIM: To study the clinical features, prognosis and outcomes of acute kidney injury 
(AKI) in patients presenting with scrub typhus, malaria, dengue fever, typhoid, 
leptospirosis and undifferentiated fever particularly to identify patients at high risk of 
developing AKI and mortality related to AFI, aiming to identify mechanisms for effective 
management using the RIFLE criteria and testing the utility of Cystatin C as a biomarker 
for diagnosis of AKI. 
 
PATIENTS AND METHODS: Consecutive in-patients with AFI were enrolled 
prospectively after admission to a tertiary care referral hospital. They were studied based 
on etiology of AFI. AKI in these patients was investigated and graded using the RIFLE 
criteria. Their presentation and course during hospital stay was studied to estimate 
morbidity, severity of AKI, dialysis requirement, mortality and evaluated for prognostic 
indicators. 
RESULTS: 163 patients were enrolled in the study and 136 patients were studied based 
on inclusion criteria. The mean age was 40.9 ± 15.6 (16 to 77 years) and sex ratio 2:1 
(male 91: female 45). AKI was observed in 71.3% and was graded using the RIFLE 
criteria as Risk (R) in 19.9%, Injury (I) in 15.4% and Failure (F) in 36%. 10 (7.4%) 
patients had hospital associated AKI. Undifferentiated fever had the highest incidence of 
AKI (94.7%) with dialysis requirement in 26.3% and death in 52.6%, while in the 
differentiated fevers AKI was commonest in malarial infection by P. falciparum (100%).  
Maximum dialysis requirement was noted in in mixed malarial infection (27.8%) and 
highest mortality in dengue fever (42.7%). Overall 26.5% patients died during hospital 
 vi
stay with 33% mortality in AKI as compared to 10.3% in the non AKI group. RIFLE 
criteria was identified as a sensitive tool for diagnosis of AKI in AFI and patients have 
worse prognosis and outcomes from R through I and F stages in terms of organ support, 
dialysis requirement and death. RIFLE staging using Cystatin C appears to be sensitive in 
diagnosing AKI in AFI earlier and may be a useful adjunct for early management. 
Fractional excretion of sodium (FENa) was useful in identifying early AKI. The Liano 
scoring at admission identified high risk patients and may be useful for triage to high 
dependency care. Renal Failure Index (RFI) was higher in those who underwent dialysis 
and died. Hemodialysis was initiated in 18.4% of whom 48% required SLED. Mortality 
in patients initiated on hemodialysis was 64% with 100% mortality in those requiring 
SLED.  
CONCLUSION: AKI has a high incidence in AFI. Application of the RIFLE criteria 
shows incremental risk for morbidity, dialysis requirement and mortality. Patients 
requiring hemodialysis have high mortality. Cystatin C has promise as a biomarker for 
early identification and management of AKI in AFI. 
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Introduction 
Acute renal failure has dominated the attention of Nephrologists for decades, with 
focused research aiming at reducing the morbidity and mortality related to the entity. 
Despite advances in diagnostics, management and dialysis related interventions the 
results have been disappointing with no significant mortality differences in last five 
decades.(1) The importance of this quest to reduce mortality and renal morbidity is 
amplified by the fact that 60% critically ill patients die during hospitalization and 13% of 
the survivors become dialysis dependent (1). In patients who recover from acute renal 
failure after variable periods of renal replacement therapy, renal insufficiency is observed 
in 41% and five year survival is about 50%. (2) This puts an additional burden on health 
infrastructure and economy. (3) 
Infectious disease resulting from established as well as novel bacterial and viral diseases 
are increasing with 13 million deaths annually. In developing countries infectious disease 
account for 50% deaths, as a result of growth of these diseases and poor care health 
infrastructure. (4) Most of these diseases are sub optimally managed in the community, 
often presenting with complications to higher centers. Alternately long hours spent in 
travel to health care centers contribute to deterioration in organ function and reserve. 
Acute renal failure has interested renal care physicians in the tropics owing to a heavy 
burden of disease related to infectious disease. Care for these patients involves an 
aggressive combination of infectious disease and clinical nephrology. 
In India it has been an understudied area with no cumulative national data on incidence of 
these diseases and related complications. Available literature has been restricted to a few 
centers of excellence on specific diseases of interest. Recent data citing renal failure in 
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41.3% with mortality of 12.1% in scrub typhus, typhoid, leptospirosis, malaria, dengue 
fever and acute undifferentiated febrile illness (5)  emphasizes a need to improve care and 
reduce in-hospital mortality and morbidity related to renal failure. The benefits of early 
diagnosis and appropriate health care interventions as a possible solution to this complex 
problem is currently undergoing intense scrutiny by the renal as well as infectious disease 
community.  
This study aims to study morbidity and mortality, identify risk factors, validate standard 
criteria for diagnosis and identify steps to improve care for patients admitted to hospitals 
in India with acute renal failure in acute febrile illness.  
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Review of Literature 
Infection is a major cause for death in South Asia and India in particular. This situation 
has been ascribed to poverty, crowding, ill hygiene, illiteracy, malnutrition, poor access 
to clean drinking water, sanitation and appropriate health care. Malaria, typhoid and 
dengue fever are common causes of morbidity and death. In the presence of poor 
reporting and indiscriminate antibiotic use, the magnitude and burden of disease are 
unreliable. Tackling the problem at the community level is further hampered by antibiotic 
resistance. (6)  
The National Commission on Macroeconomics and Health identified infection and vector 
borne disease to be a significant health problem in India, with 1.6% of the total burden of 
disease and 4200 disability adjusted life years (DALYS) lost in 1996. Comparatively 
tuberculosis was reported at 2.8% with 7577 DALYS. This translates to huge numbers 
related to malaria and other vector borne diseases like dengue fever, which are 
prominently mentioned in the report.(7) 
Acute febrile illness (AFI) is commonly seen in the community and managed by local 
health care practitioners, empirically with anti-malarials and antibiotics in most cases. 
Thereafter they are referred to or find their way to higher centers especially if 
unresponsive to these medications. Acute undifferentiated fever constitute about 30-50% 
of these patients presenting to hospitals with fever. They do not have a localizing cause 
for fever and remain undiagnosed after a standard work up for fever using blood counts, 
liver enzymes, chest roentgenogram, ultrasound and blood smears for malaria, which are 
usually available at most local centers.  
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Diagnosis and management require a stepwise approach with careful blood film 
microscopy, serological testing and cultures of blood and available fluid. Investigating 
these require an intricate knowledge of loco-regional diseases to improve diagnosis and 
reduce costs related to investigation and better outcomes as a result of early appropriate 
interventions.  
In a study during the monsoons of 2006 in Mumbai 2214 patients with AFI were 
investigated and 53.75% had undifferentiated fever. Amongst the others 22.5% had 
malaria, 21.8% had leptospirosis and 1.88% had dengue. 160 patients died of whom 
23.12% had acute renal failure (ARF) with acute respiratory distress syndrome (ARDS), 
15% had ARDS with hepatorenal failure, 11.25% had hepatorenal failure and 15.62% 
had isolated ARF. (8)  
Data from Vellore, Tamil Nadu, has highlighted a significant burden of disease related to 
undifferentiated AFI and a diagnostic algorithm was proposed for diagnosis of these 
patients. Scrub typhus, malaria, dengue fever, typhoid, leptospirosis, spotted fever 
rickettsiosis and Hanta virus infection was diagnosed in 47.5%, 17.1%, 7%, 8%, 3%, 
1.8% and 0.3% respectively with an overall mortality of 12.1%. (9) 
Scrub typhus presented with multi organ dysfunction characterized by leucocytosis with 
transaminitis, tell tale eschar, febrile defervesence with doxicycline, aseptic meningitis 
and respiratory embarrassment progressing to ARDS. Malaria presented with varying 
grades of clinical severity, splenomegaly, thrombocytopenia and hepatorenal 
decompensation characterized by mixed hyperbilirubinemia, transaminitis and renal 
failure. Dengue fever (DF), dengue hemorrhagic fever (DHF) and dengue shock 
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syndrome (DSS) presented with bleeding manifestations, leucopenia, thrombocytopenia 
and overt bleeding. Typhoid fever presented with diarrhea and leucopenia.(9)  
Evidence based diagnostic and management algorithms offer scope for better 
management of patients at a secondary level, where multiorgan dysfunction and renal 
failure, often result in death. 
ARF has been commonly described in malaria, leptospirosis, melioidosis, shigellosis, 
cholera and diarrheal disease from tropical countries.(10) The incidence of infection 
related ARF has been increasing in India in the past few decades, (11) infective causes 
like sepsis, leptospirosis and malaria accounting for 9.3, 7.8% and 7.5% respectively. 
(12) This contrasts to childhood diarrhea which has improved in terms of incidence and 
mortality as a result of community based health programs and awareness by 
governmental as well as non governmental organizations.(13)  
Malaria, leptospirosis, dengue fever and malaria related ARF are a major cause of 
morbidity and death. (14)(15) Emergence of new diseases, particularly zoonotic and 
vector borne diseases, along with better diagnostic and surveillance facilities, has added 
to this burden in India. (16) 
Infection related ARF has a high rate of complications despite optimal management. 
Moderate to severe ARF occurs in 1.5 % hospital admissions in India. (17) In-hospital 
mortality in ARF is higher than for those without ARF (42.7% versus 13.4%) (18) and 
deaths related to ARF in sepsis far exceed those not resulting from sepsis (74.5% versus 
45.2%). (19) Intervention with dialysis is required in 69% and persistent dialysis-
dependent renal failure in 8.18% patients. (12) However, data on ARF in infectious 
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disease in India continues to be sparse, especially their incidence, outcomes and 
intervention, particularly so in zoonotic and vector borne diseases. 
A concomitant study group of the Vellore study evaluated renal manifestations and 
interventions for those presenting with acute kidney injury (AKI) in AFI. This study for 
the first time utilized the RIFLE criteria and validated its utility in patients presenting 
with AFI and ARF. It generated a baseline glomerular filtration rate (GFR) from the 
Modification of Diet in Renal Disease (MDRD) equation (whenever a baseline creatinine 
was unavailable) and utilized serial creatinine measurements to track AKI during the 
admission and period of hospital stay. (5) 
AKI was observed in falciparum malaria, scrub typhus, typhoid fever, mixed malarial 
infection, dengue, and leptospirosis in 63.2%, 42.6%, 8.7%, 7.6%, 6.5% and 3.3% 
respectively. Overall 41.1% patients had AKI. 17.4%, 9.3% and 14.4% of these patients 
were categorized to Risk (R), Injury (I) and Failure (F) of the RIFLE classification of 
AKI respectively with an incremental risk for death and requirement for dialysis seen 
across the groups from R to F. While the overall mortality was 12.3% the risk of death 
based on initial RIFLE category was unavailable.(5) 
Renal involvement in AFI is not clearly elucidated and pathophysiology of AKI in AFI is 
an evolving area of interest. An understanding of the disease and related pathophysiology 
enables early identification, appropriate management and early intervention. 
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Scrub typhus  
Scrub typhus is an endemic febrile illness with a multisystemic presentation characterized 
by rash, fever, localized lymphadenopathy and an eschar at the site of the bite of a 
chigger (larva stage) thrombiculid mite transmitting Orientia tsutsugamushi.  
The incubation period ranges from 7-15 days. Rickettsial proliferation on small vessel 
endothelium damages its integrity leading to endothelial dysfunction, cytokine release 
and a polymorphic response. This results in platelet aggregation, micro infarction and 
gangrene.  (20) This focal or diffused vasculitis/perivasculitis causes pulmonary, hepatic, 
neural, cardiac and splenic manifestations.  
Till recently ARF in scrub typhus has been infrequently reported with predominant renal 
involvement in the disease attributed to pre renal causes like sepsis/hypovolemia and 
secondary to increased vascular permeability and hypoalbuminemia. (21)  Vasculitis and 
interstitial nephritis are other proposed pathophysiological mechanisms. (22)  A case 
report has documented direct invasion by the O. tsutsugamushi cocobacillus in the renal 
interstitium and acute tubular necrosis with tubular deposition. Glomerular involvement 
in scrub typus is not reported and is an area of evolving interest. (23) 
Whenever available diagnosis is confirmed by Weil-Felix heterophile antibody testing to 
Proteus mirabilis, which may be negative in about 50% patients. Microagglutination 
testing (MAT), immunoflourescent antibody testing (IFAT), enzyme linked 
immunosorbent assay (ELISA) and polymerase chain reaction (PCR) are the other 
alternatives. Contiguous presence of hepatic transaminitis, thrombocytopenia and high 
leucocyte counts is predictive of scrub typhus with specificity and sensitivity of 80%. The 
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case fatality rate is 14% with renal dysfunction (creatinine >1.4 mg%) being a predictor 
of  death (relative risk 43.99). (24)  
Scrub typhus responds to an empirical course of doxicycline.  Early recognition and 
treatment with doxicycline, tetracycline, azithromycin or telithromycin is life saving. 
Rifampicin is a suitable alternative in unresponsive patients.(25) Prophylaxis with weekly 
doxicycline especially for medical personnel in endemic areas should be considered.(20)  
In the Vellore data 42.6% patients had AKI. R was seen in 20.2%, I in 21% and F in 
11.2%, with dialysis requirement in 5.9% patients and mortality in 13.3%. (5) Renal 
failure should be managed early in the pre renal failure with aggressive hydration and 
dialysis support when indicated by standard indications. 
Malaria 
Malaria is endemic in India with 80.5% of the population at risk for the disease. The 
National Vector Borne Control Program reports about 1.5 million cases in India of which 
53 % are reported as falciparum malaria.(26) The speculative low number of cases 
reflects wide distribution, poor access to patients and under reporting of the disease. 
Malaria is caused by infestation of the Plasmodium species transmitted by the bite of 
anopheles mosquito. Malarial infection is caused by the four species Plasmodium vivax, 
Plasmodium falciparum, Plasmodium malariae and Plasmodium ovale, either alone or in 
combination. In combination the disease is referred to as mixed malarial infection. 
The anopheline mosquito transmits sporozoites to the blood stream during its blood meal 
and within hours sporozoites invade hepatocytes, dividing into exoerythrocytic 
merozoites. These leave the liver, invade red blood cells (RBC s) developing into ring 
shaped, vacuolated trophozoites. These divide into merozoites which lyse the RBC s and 
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invade other unaffected RBC s in a process referred to as blood schizogony. This process 
occurs every 48 hours in P. falciparm. In non immune individuals the process of 
destruction is magnified several fold. 
While fever is a cardinal presentation other manifestations may vary such as headache, 
chills, diaphoresis, myalgia and vomiting in uncomplicated disease or seizures, altered 
sensorium, renal failure, hepatitis and ARDS in severe disease.  Indicators of severe 
malaria and poor prognosis are listed. (Table 1) (27) 
Severe disease which is often fatal results in 1.5 – 2.0 million deaths annually world 
wide. (28) In non endemic areas history of travel from an endemic region provides 
diagnostic clues to an underlying malarial infection.   
Malaria is reliably diagnosed using thick and thin smears with a sensitivity of 90% and 
parasitic index expressed as a percentage of parasitized RBC s or parasites visualized in 
each microlitre of blood. Although one well examined negative smear is indicative of the 
absence of the disease repeat examinations are encouraged. Alternatively in areas where 
microscopy is not possible dipstick assays may be a good alternative, although the false 
negatives are reported. (29) 
ARF occurs in 13-17.8% cases, particularly in those with heavy parasitemia and 
hemolysis, manifested by oliguria or anuria secondary to ischemic injury. 
Hemoglobinuria secondary to massive hemolysis may present with ‘Blackwater Fever.’ 
Acute tubular necrosis (ATN) is the most common biopsy picture. Metabolic acidosis and 
hyperkalemia are common complications.  Patients with severe renal failure often require 
dialysis, for anuria, hyperkalemia and metabolic acidosis, till recovery of renal function. 
Ideally patients with severe disease should be managed in a high dependency unit as 
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mortality in this group of patients is as high as 29%.(29) In the Vellore data malaria 
related AKI was seen in 59.6% of those with P.falciparum and mixed malaria, requiring 
dialysis in 40.4% and death in 17.4% patients. In patients with P. vivax malaria no deaths 
were reported. (5)  
 
Table 1. Indicators of severe malaria and poor prognosis. (27) 
Manifestation Features 
Cerebral malaria Unrousable coma not attributable to any other cause, with a Glasgow Coma Scale score 
≤ 9. Coma should persist for at least 30 min after a generalized convulsion 
Severe anemia Hematocrit <15% or Hb < 50 g/l in the presence of parasite count >10 000/μl 
Renal failure Urine output <400 ml/24 hours in adults (<12 ml/kg/24 hours in children) and a serum 
creatinine>265 μmol/l (> 3.0 mg/dl) despite adequate volume repletion 
Pulmonary edema and 
ARDS 
The acute lung injury score is calculated on the basis of radiographic densities, severity 
of hypoxemia, and positive end-expiratory pressure  
Hypoglycemia Whole blood glucose concentration <2.2 mmol/l (<40 mg/dl) 
Circulatory collapse 
(algid malaria) 
Systolic blood pressure <70 mmHg in patients > 5 years of age (< 50 mmHg in children 
aged 1–5 years), with cold clammy skin or a core-skin temperature difference >10°C 
Abnormal bleeding 
and/or DIC 
Spontaneous bleeding from gums, nose, gastrointestinal tract, or laboratory evidence of 
disseminated intravascular coagulation 
Repeated convulsions ≥ 3 generalised convulsions observed within 24 hours 
Acidemia/acidosis Arterial pH <7.25 or acidosis (plasma bicarbonate <15 mmol/l) 
Hemoglobinuria Hemolysis not secondary to glucose-6-phosphate dehydrogenase deficiency 
Impaired consciousness Rousable mental condition 
Prostration or weakness  
Hyperparasitemia > 5% parasitized erythrocytes or > 250 000 parasites/μl (nonimmune individuals) 
Hyperpyrexia Core body temperature >40°C 
Hyperbilirubinemia Total bilirubin >43 μmol/l (> 2.5 mg/dl) 
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Dengue Fever, Dengue Hemorrhagic Fever and Dengue Shock Syndrome  
Dengue fever (DF) is a mosquito (Aedes aegypti) borne fever caused by RNA viruses 
DEN-1, DEN-2, DEN-3 and DEN-4 of the genus Flavivirus. It has epidemic transmission 
and the World Health Organization (WHO) estimates 2.5 billion people at risk for the 
infection with 20000-25000 deaths in about 50 million people affected by the disease 
annually.(30) It is hyperendemic in South East Asia and India, DEN-3 being the 
commonest form found in India.  
Although DF started as an urban disease it has a presence in both rural and urban areas 
due to water stagnation, travel, migration, crowding and poor vector control. Mosquito 
control is the only effective preventive strategy. After infection by a blood meal 
antibodies are generated against non structural (NS) proteins of the virus causing 
endothelial injury, cytokine release and cell injury. A protein NS-3 stimulates CD4 and 
CD8 cells and high levels of interferon gamma, tumor necrosis factor alpha and beta lyse 
dengue virus (DV) infected cells. Endothelial dysfunction and a resultant capillary leak 
syndrome are compounded by impaired homeostasis, altered leucocyte function, 
coagulation defects, thrombocytopenia and hepatic dysfunction. (31) Once infected the 
incubation period ranges from 3-14 days and based on the severity of disease presentation 
it has been termed as Dengue Fever (DF), Dengue Hemorrhagic Fever (DHF) and 
Dengue Shock Syndrome (DSS).  
It presents with a clinical syndrome characterized by saddleback pattern of fever, 
headache, myalgia, arthralgia and rash in DF and in addition hemorrhagic manifestations 
of varying severity in DHF.(32)  Hemoconcentration, lymphocytosis and 
thrombocytopenia with transaminitis in DF and in addition prolonged partial 
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thromboplastin time, low fibrinogen level and increased fibrinogen degradation products 
in DHF and DSS is observed. Diagnosis is confirmed by isolation of the virus, detection 
of the viral antigen or viral RNA in serum / tissues or viral specific antibodies in serum. 
Antibody testing is routinely used in clinical scenarios for diagnosis and reaches a peak 
level for detection about 7-14 days after the bite. (Figure1)(31) 
 
Figure 1. Antibody detection in dengue fever. (31) 
 
 
ARF in DF was previously thought to be rare and explained by ATN secondary to 
hypotension.(33)  However studies have documented an increasing trend of ARF from 
0.3% in 2005 in Thailand, (34) to 3.3% in 2009 in Taiwan.(35) Case reports have 
documented renal failure with Hemolytic Uremic Syndrome (HUS), (36) myositis (37) 
and rhabdomyolysis.(38) Immune complex disease is considered less likely although DV 
particles have been isolated in the kidney, as the complexes are small enough to be 
filtered and are considered likely only in kidneys having suffered glomerular injury 
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previously.   However glomerular involvement is documented in an older series showing 
mesangial and endothelial hyperplasia with IgG, IgM and C3 deposition in capillary 
walls.(39) Mice after innnoculation of DEN-2 have shown proliferative glomerular injury 
on biopsy in one study and increased endocapillary and mesangial hypercellularity in 
another. (40)(41)  
DSS is an independent factor for AKI in DF. (42) Data from Vellore, has documented an 
incidence of 35.7% AKI in patients with DF. RIFLE grades R in 14.3%, I in 3.6% and F 
in 17.9% with hemodialysis requirement in 7.1% and death in 25 % are observed.(5)  In 
patients with severe renal failure and having indications for dialysis Continuous Renal 
Replacement Therapy (CRRT) has been suggested as an alternate to conventional 
hemodialysis. (43)  
Leptospirosis 
Leptospirosis is a biphasic illness caused by the spirochete Leptospira interrogans. It has 
a presence across all inhabited continents, with a prevalence of 10-100 per 100000 in 
tropical areas.  (44)  
Leptospira are spread to man by shedding in the infected urine of a reservoir of animals, 
usually rats, and transmitted through cuts, bruises, conjunctiva or oral ingestion while 
working in fields, barns, water logged areas and sewers. 
Pathophysiology of renal involvement in Leptospirosis is explained by an immune / 
allergenic response to leptospiral endotoxins inhibiting the Na-K ATPase in renal tubules 
and a generalized vasoconstriction and hypovolemia as a result of the endotoxemia. 
Leptospirosis presents as an innocuous self limiting anicteric disease in 85-90%, but in 
the remaining who suffer the icteric form the presentation is with jaundice, sub-
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conjunctival hemorrhage and systemic manifestations. Renal manifestations include 
azotemia, oliguria and anuria, usually appearing in the second week of the illness. 
Urinalysis shows hematuria, casts and pyuria.  
Although renal involvement is documented in both forms it is symptomatic and severe in 
the icteric form, often with severe oliguric renal failure and poor prognosis. ARF presents 
with ATN and acute interstitial nephritis (AIN) in 16-40% of patients with severe 
infection.(45) Leptospira induced ARF in tropical areas may occur in 44-67%.(46) In a 
study from Romania, ARF presented predominantly as multiorgan failure leading to 
death in 26% and mild persistent renal failure in 10% of the survivors. Post mortem renal 
biopsy available in 15 patients showed AIN and ATN in the majority (14 and 13 patients 
respectively) with features of acute vasculitis in four patients. (47)  
Renal failure has also been associated with rhabdomyolysis and thrombocytopenia. (48) 
Proximal tubular dysfunction is common with high distal sodium delivery and potassium 
loss in the normal distal tubule and resultant hypokalemia.  High fractional excretion of 
sodium with potassium loss in excess of 1000 mEq/day has been reported even in volume 
depletion. (47)  
Although renal complications occur in the second or third week of illness, they may 
occur as early as the first week. Onset of diuresis in anuric patients is a sign of renal 
recovery. Other involvement in severe disease includes hepatic, pulmonary and neural 
involvement. The average mortality rate is 10% in confirmed cases worldwide. 
Post Graduate Institute of Medical Education and Research in Chandigarh have reported 
a rising incidence of leptospirosis from 11.7% in 2004 to 20.5% in 2008, with peak 
numbers during the rainy season. Renal failure was observed in 60.5% and was the 
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commonest complication as compared to respiratory failure in 20.9%, neuroleptospirosis 
in 11.6% and disseminated intravascular coagulation (DIC) in 11.6%. The case fatality 
rate was 5.9%.(49) Another study has shown a case fatality of 7.7% (50) 
Data from Chennai shows a decline of ARF in leptospirosis from 31% to 7.5% over a 
period from 1987 to 2004. (12) This decline has been attributed to improved awareness, 
better diagnostics, reduced seroprevalence of virulent Leptospira autumnalis and early 
empirical treatment with doxicycline. (51) In data from Vellore AKI was present in 
50.0% of whom 25.0% presented in RIFLE R and 8.3% and 16.7% in I and F 
respectively with no patients requiring hemodialysis or any deaths.(5) ARF in 
leptospirosis has a significant mortality especially due to delay in diagnosis and late 
institution of treatment with penicillin.(52)   
Typhoid Fever 
Typhoid is a systemic infection caused by Salmonella typhoid and has a rising global 
presence with about 260000-600000 deaths annually worldwide and a crude incidence 
across Asia of 274/100000 population. (53) These range from 15.3 per 100000 in China 
to 451.7 per 100000 in Pakistan and is endemic in most developing countries including 
India.  Incidence in India has been reported from 136.7/100000 population (54) -
980/100000 (55)  and mortality of 10 - 15 % as a result of disease related 
complications.(56)  
Typhoid presents with fever and abdominal symptoms, which if untreated progress to 
severe disease manifested by altered sensorium, shock and multi organ dysfunction 
syndrome (MODS). Blood culture continues to be the gold standard for diagnosis 
detecting about 70% of patients with suspected typhoid fever.  Serological tests like the 
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Widal test continue to be used in endemic areas with a high sensitivity in detecting 
typhoid. It is however hampered by differing rates of sensitivity and specificity across 
populations. Other tissues like bone marrow and stool cultures can detect Salmonella in 
85-95% and 45-65% respectively.(57) 
Renal involvement in typhoid occurs in 0-6% of typhoid with glomerular as well as 
tubular injury manifested by renal failure, microscopic hematuria and proteinuria. 
Dehydration and rhabdomyolysis are incriminated in ARF, as is reversible endothelial 
dysfunction secondary to the Salmonella toxin. It occurs in about 3.9% patients and is 
usually responsive to treatment and hydration.  
 ARF in typhoid fever has also been reported with intravascular hemolysis, 
rhabdomyolysis and severe jaundice.   
Absence of renal histology in most cases makes it difficult to predict the exact nature of 
pathology with conviction. In addition, the bacillus has not been isolated in available 
renal tissue and toxin induced or immune mediated nephropathy is more likely. (55) The 
kidneys involved as a sequalae of immune complex glomerulitis are found to be self 
resolving on serial renal biopsies.(58) Isolation of salmonella Vi antigen in a case report 
from the glomerular capillaries may not entirely rule out the possibility of direct 
involvement. (58) 
Data from Vellore has documented an incidence of 6.2 % renal failure in patients with 
typhoid with 3.1% each in the injury and failure groups.(5)  
Undifferentiated Fever 
Undifferentiated fever (UF) is defined as fever less than two weeks duration without any 
localized source of infection. A study from central India revealed a significant proportion 
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of fever to be non malarial acute undifferentiated fever, managed emperically with anti 
malarials despite laboratory evidence pointing to an alternate diagnosis (88% non 
malarial acute undifferentiated fever with 39.9 % of these patients treated with anti 
malarials). (59) In another study, from Mumbai studying the pattern of 160 deaths in 
patients with AFI in 2006, 53.75% were undifferentiated despite detailed evaluation 
including a post mortem. About 23% had ARDS with renal failure, 11% with hepatorenal 
failure and 11% had isolated renal failure. (60) 
Data from the Vellore study showed undifferentiated fever in 8.4% with AKI in 35.5% of 
whom RIFLE R constituted 9.7%, I 19.4% and F 19.4%, with hemodialysis requirement 
in 6.5% and death in 19.4%. (5) 
These fevers are often sub optimally evaluated owing to paucity of funds and diagnostic 
facilities and managed emperically with anti malarials (59) Awareness about the UF and 
the need to further delineate etiology in this group is the need for the hour, particularly 
because in the absence of targeted therapy morbidity and mortality continues to be high. 
Identifying AFI etiology based on the above profile is challenging as red flags in 
identifying them are useful. (Figure 2) 
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Figure 2. Red Flags in Acute Febrile Illness - Adapted from Chrispal A, et al. (9) 
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Acute Kidney Injury 
Acute Kidney Injury (AKI) is defined by “an abrupt increase in serum creatinine over 48 
hours resulting from an injury or insult that causes a functional or structural change in the 
kidney.” It predisposes to chronic kidney disease and progresses thereafter to ESRD and 
death. (Figure 3) In critically ill patients severe renal failure requiring dialysis occurs in 
4-5 % with a mortality rate of 60%. About 8-22% of these patients continue to require 
maintenance dialysis support thereafter. (61)  
Pathophysiology of AKI  
AKI has a common pathophysiological process despite its multifactorial etiology. (Figure 
4) The commonest injury in hospital is ischemic or toxic, resulting in a downward spiral 
to AKI and ESRD if not evaluated or managed early. Once renal perfusion is reduced 
ischemic tubular dysfunction leads to loss of tubular cell polarity, followed by apoptosis 
and necrosis. Loss of ß-integrins and adhesion molecules cause sloughing of the tubular 
cells and the sloughed viable as well as necrotic cells lead to tubular obstruction and 
production of inflammatory mediators. These induce interstitial inflammation and 
vascular congestion. Once cells are sloughed, back-leak of filtrate occurs owing to 
increased intra-tubular pressure, worsening the inflammation cascade and ischemia as a 
result of vasoconstriction. The kidney may recover if the underlying insult is reversed 
early by a process of intact epithelial cells migrating over the denuded areas of the 
basement membrane, cell de-differentiation and proliferation to restore structural and 
functional integrity over a period of time. Time is of essence in this process of healing, 
with timely intervention resulting in regression of injury and recovery.(62) 
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Figure 3. Progression of AKI and complications. (63) 
 
 
 
 
 
 
 
 
 21
Figure 4. Pathophysiology of AKI. (62) 
 
 
 
Acute Kidney Injury: The process of development.  
 “The exact definition of a problem with a detailed description and accurate 
measurement of the factors involved provides already half the solution.”—Anonymous.   
The problem with definitions like the above mentioned one is poor standardization both 
in terms of diagnosis and grading the severity of AKI. It was noticed that even modest 
increases in creatinine from the baseline translated to increased risk of mortality. A need 
to factor the risk associated with this rise in a manner that would sensitize treating 
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physicians to treat early as well as grade / prognosticate patients based on the severity of 
AKI was felt.  
The Acute Dialysis Quality Initiative (ADQI) was born out of this long felt need to 
address AKI and related issues. The group comprised intensivists and nephrologists from 
the American Society of Nephrology (ASN), International Society of Nephrology (ISN), 
National Kidney Foundation (NKF) and the European Society of Intensive Care. They 
met in Vicenza, Italy, in September 2004 to generate protocols and guidelines aiming to 
standardize care and dialysis for the critically ill with AKI.  
Their guidelines called the RIFLE criteria (Figure 5) graded AKI based on the rise in 
creatinine and decrease in urine output into Risk (R) where renal failure can be 
prevented, Injury (I) where damage is ongoing and Failure (F) where renal failure is 
established. Creatinine was used despite reservations regarding its applicability as it is 
widely available and affordable as a marker for tubular dysfunction. (64)  
Figure 5. RIFLE Criteria. (64) 
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RIFLE Classification 
AKI has been a significant component of critical care scoring systems constituting 20% 
and 16.6% of the APACHE III (Acute Physiology and Chronic Health evaluation) (66) 
and SOFA (Sequential Organ Failure Assessment) scores. (67) ADQI formulated RIFLE 
grading AKI based on increasing severity (assessed by fall in urine output and rise in 
creatinine from baseline) as R (Risk), I (Injury) and F (Failure) and outcomes as L (Loss) 
and E (End Stage Renal Disease).(64) It has been validated in patients with renal failure 
in acute febrile illness (5) as well as critically ill hospitalized patients. (68) In patients 
presenting with AKI in AFI the incidence of AKI was 41.1% with 17.4%, 9.3% and 
14.4% in the RIFLE R, I and F categories respectively. Mortality across the groups was 
12.3 % with an incremental risk for requirement of hemodialysis and mortality from risk 
to failure. (5) In ICU s the incidence of AKI in patients in the R and I categories is 55% 
placing them at a higher risk of mortality.(69) In patients requiring renal replacement 
therapy (RRT) the overall in hospital mortality in two studies is 50.2% (70) and 76%. 
(61) 
Limitations 
Although the introduction of RIFLE provided insight into the high incidence of AKI and 
enabled early diagnosis and management, the criteria per se is not without limitations, in 
a practical scenario. Although urine output serves as a sensitive and specific parameter in 
the criteria, its accuracy in terms of measurement in a patient who is not on continuous 
bladder drainage or post diuretic use is questionable. Comparing these parameters has 
shown creatinine criteria to be a better marker for mortality, but in conjunction with urine 
output a stable result is likely.(71) The absence of a baseline creatinine in most patients 
 25
presenting with AKI does hamper accuracy of the criteria, although back calculation of 
baseline GFR using the MDRD equation has been advocated.(68) 
RIFLE has also been validated successfully in non ICU based situations. In a 
retrospective study RIFLE; R, I and F were found in 9.1%, 5.2% and 3.7% respectively 
with overall mortality of 8.0%. An incremental mortality was observed from the non AKI 
patients across to those in failure (non AKI- 4.4%; R - 15.1%; I - 29.2%; and F - 41.1%). 
(72) 
Acute Kidney Injury Network Criteria 
AKIN is an international group of nephrologists including adult, pediatric and critical 
care specialists with a focused interest in AKI and development of evidenced based 
guidelines for improvement in care and outcomes of AKI.(65) They defined AKI as “an 
abrupt (within 48 hours) reduction in kidney function defined as an absolute increase in 
serum creatinine of more than or equal to 0.3 mg/dl (≥26.4 μmol/l), a percentage increase 
in serum creatinine of more than or equal to 50% (1.5-fold from baseline), or a reduction 
in urine output (oliguria of less than 0.5 ml/kg per hour for more than six hours).” 
Urine output is used as a diagnostic criterion as it often heralds renal dysfunction before a 
rise in serum creatinine. It needs to be assessed in the clinical scenario of reliable 
measurement, optimal hydration, absence of diuretic use and urinary obstruction with the 
recognition that it may not be specific for in AKI stage I.(65) 
AKIN versus RIFLE Criteria  
 A recent analysis of the Australian New Zealand Intensive Care Society (ANZICS) 
database found agreement with both RIFLE and AKIN criteria. There was <1% 
difference in the overall number of identified AKI with AKIN, slightly increasing the 
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number of patients classified as Stage I injury  as compared to category R in RIFLE (18.1 
versus 16.2%) but reducing those with Stage II injury as compared to category I in 
RIFLE (10.1% versus 13.6%). ROC curves for hospital mortality were similar (0.67 for 
AKIN and 0.66 for RIFLE. (73) This similarity has been demonstrated in other studies 
with a similar design.(74) 
As there seem to be no additional benefits to the AKIN criteria at this point, future efforts 
aim to focus on successful application and extended use of either of these criteria, 
particularly RIFLE, as a surrogate marker for outcomes in trials to prevent and alleviate 
AKI.(73) 
The Liano Scoring System for ARF 
Liaño F and Pascual J conducted the first community based prospective study on ARF in 
1996 generating data on epidemiology, etiology, clinical features and outcomes with an 
aim to initiate preventive strategies for ARF in Spain. Mortality of 45% with corrected 
mortality for ARF of 16.7% was observed. Patients requiring dialysis had a higher 
mortality of 65.9% and coma, assisted respiration, hypotension, jaundice and oliguria 
were found to be poor prognostic indicators. Based on the severity of ARF an expected 
outcome was calculated using the severity index which co related well with the observed 
clinical outcomes. 
Severity of illness is scored using the Liano scoring measured by the formula  
(0.032 * age in decades - 0.086 * male gender - 0.109 * nephrotoxic + 0.109 * oliguria + 
0.116 * hypotension + 0.122 * jaundice + 0.150 * coma - 0.154 * consciousness + 0.182 
* assisted respiration + 0.210) (75)  
 27
The Madrid study co relates well with others studies on ARF and related outcomes. (76) 
It has been validated recently in the Indian population with a sensitivity of 60.7% and 
specificity of 100%.(77) 
The Vellore Model  
Recognizing the need to develop an effective renal sensitive marker for ARF the Vellore 
model was developed in 2005. It compares favorably to generic predictive models like 
APACHE III, SAPS2 and Laino score. This model factored in parameters indicative of 
poor outcome like age, sex, oliguria, hypotension, jaundice, coma, assisted ventilation, 
hypoalbuminemia, sepsis and hospital acquired ARF to arrive at probability of death 
using the equation: ey/1+ey  
y = (0.0196 * Age) – (0.5855 * male gender) + (1.5887 * oliguria) + (1.1427 * 
hypotension) + (1.3068 * jaundice) + (2.3466 * coma) + (0.8612 * assisted ventilation) + 
(0.5423 * hypoalbuminemia) + (0:7960 * sepsis) + (0.8389 * hospital acquired ARF) – 
3.4741. 
It is validated and found to be a useful predictive tool for ARF with good calibration. 
Sepsis and hospital acquired ARF herald poor outcomes using a discriminant score of 0.5 
as cut off. Positive predictive value of 90% with 70% sensitivity was achieved for a 
population with tropical ARF.(78)  
Biomarkers 
Renal function is estimated by glomerular filtration rate. The gold standard for 
measurement is by inulin clearance or radio isotope measures, which are impractical in 
acute critical care settings. In this scenarion creatinine is used as a poor but easily 
available substitute.  
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It is widely recognised that the Achilles heel of AKI management continues to be late 
diagnosis, not withstanding advances and improvement based on RIFLE and AKIN. This 
is owing to reliance on creatinine as marker which lags in detecting injury as well as 
recovery (79) and whose levels are modified in critical illness. (80) In addition, it is 
unable to convey any information regarding the site of renal injury (proximal or distal 
tubular, interstitial or vascular), duration of injury (pre renal, renal or post renal), etiology 
(ischemic, toxin or sepsis mediated), stratify risk or prognosticate the renal injury.(81)  
A good biomarker aims to fulfil these properties and opposed to creatinine aims to detect 
tubular injury prior to decrease in filtration.   
An abundance of research in biomarkers for AKI has identified cystatin C (CC), kidney 
injury molecule 1(KIM 1), neutrophil gelatinase–associated lipocalin (NGAL), 
interleukin 18 (IL-18), sodium/hydrogen exchanger isoform 3 (NHE 3), N-acetyl-β-d-
glucosaminidase (NAG), and matrix metalloproteinase 9 (MMP 9) as markers of 
promise. 
Cystatin C is considered an alternative to creatinine which is unmodified by age, weight 
and gender and is sensitive to incepient renal injury, being able to antedate renal injury as 
compared to creatinine.(82) 
NGAL and KIM 3 are increased in urine as early as two hours after injury and IL-18 at 
12 h which may serve as early detection biomarkers. These however await validation and 
standardization prior to widespread use and acceptability.(83) Promising biomarkers 
(Figure 6) and their utility in identifying AKI ( Figure 7) is undergoing intense scrutiny. 
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Figure 6.  Promising AKI biomarkers and related pathophysiology. (62) 
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Figure 7. AKI indentification using biomarkers.  
 
 
 
Renal Replacement Therapy in AKI 
Nephrologists have always been challenged by the need to generate evidence based 
guidelines on indications for dialysis in AKI. When to initiate and withhold dialysis 
currently depends to a large extent on personal opinion.  
Dialysis in AKI has been based metabolic parameters, attending renal physician’s 
preferences for early or late initiation, availability of resources or empiricism. Standard 
indications for dialysis include absolute indications like blood urea nitrogen more than 
100 mg/dL, hyperkalemia (potassium more than 6 meq/dL) with ECG abnormalities, 
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severe metabolic acidosis (pH less than 7.15), hypermagnesemia (Mg more than 8 
meq/dL) with anuria and absent deep tendon reflexes and diuretic resistant fluid overload. 
Relative indications include blood urea nitrogen greater than 76 mg/dL, dysnatremia, 
hypermagnesemia (Mg more than 8 meq/dL), metabolic acidosis (pH more than 7.15), 
oliguria / anuria or diuretic sensitive fluid overload.  
AKIN attempted to provide evidence based guidelines for initiation and discontinuation 
of dialysis but available evidence in literature is not adequately powered to provide the 
answers at present. It hopes to answer the question with a prospective study of AKI adults 
in ICU settings with standardized urea clearance and targets for initiation and 
discontinuation (GFR 20 ml/min based on the physicians discretion) and follow up for a 
year after discharge.(84) 
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Objectives 
1. This study was undertaken to evaluate the clinical features, prognosis and outcomes of 
acute kidney injury (AKI) in patients presenting with tropical acute febrile illnesses (AFI) 
such as scrub typhus, malaria, dengue fever, typhoid, leptospirosis and undifferentiated 
fever. 
2. Identify patients at high risk of developing AKI and mortality related to AFI. 
3. Identify mechanisms for effective management and utility of RIFLE criteria for AKI in 
AFI. 
4. Evaluate Cystatin C as a biomarker for diagnosis of AKI. 
5. Indications and outcomes of hemodialysis in AFI related AKI. 
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Patients and Methods 
The research proposal was submitted to and discussed at the Institutional Review Board 
(IRB) and Ethics Committee (EC). IRB and EC consent were obtained prior to 
proceeding with the study. Patients admitted to the Internal Medicine general wards, high 
dependency and intensive care unit with AFI and AKI during the period of 1st January 
2010 to 30th September 2010 were invited to participate in the study. Once identified 
from the hospital database, these patients were screened by the primary investigator with 
a clinical history and examination to exclude fever as a result of localized infection or 
other systemic non infectious causes. They were invited to participate in the study and if 
willing to do so, an informed consent was obtained and recruited into the study. 
(Annexure1)  
All patients were evaluated with a hemogram, creatinine, electrolytes, thin smears for 
malaria, blood culture and chest X-ray (CXR). Urine or other fluid cultures were done 
whenever indicated. A blood and urine sample was collected at recruitment and suitably 
stored.  
The patients were screened for the presence of dengue fever, leptospirosis, typhoid, 
spotted fever and scrub typhus with case definitions for the diseases. (Table 3) This 
febrile work up was initiated in the ER or on admission to the ward and for those without 
a clear diagnosis at discharge the stored sera was used to complete evaluation with 
serology for scrub typhus, typhoid, leptospirosis and dengue fever. 
These patients were followed up during hospital stay and accrued data reviewed after 
discharge to establish an etiology and analyze their presentation, management as well as 
complications, intervention with hemodialysis and outcome at discharge.  
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Table 3 Diagnostic criteria for Acute Febrile Illness. (9) 
 
MALARIA 
  CASE DEFINITION
DEFINITE 
CASE 
Falciparum Malaria – AFI + Plasmodium falciparum visualised on 
thin blood smear 
  Vivax Malaria – AFI + Plasmodium Vivax visualised on thin blood 
smear 
  Mixed Malaria – AFI + Plasmodium falciparum and Plasmodium 
Vivax visualised on thin blood smear 
 
 
SCRUB TYPHUS 
  CASE DEFINITION
DEFINITE 
CASE 
Acute Febrile illness + Definite Eschar 
 Acute Febrile Illness + Scrub Typhus Elisa Positive + Febrile 
Response to Doxycycline < 48 hrs 
  Acute Febrile Illness + Scrub Typhus ELISA sero-conversion in 
convalescent sera 
PROBABLE 
CASE 
Acute Febrile Illness + Scrub Typhus Elisa Positive + Other serology 
negative (BUT defervesence data not available) 
 Acute Febrile Illness + Multisystem involvement + Scrub Elisa 
Positive + Other serology are negative (BUT defervesence occurs 
upto 96hrs) 
  Acute Febrile Illness + Multisystem involvement + Febrile response 
to Doxycycline <48hrs + Other serology are negative (BUT Scrub 
Typhus serology negative) 
 
 
ENTERIC FEVER – SALMONELLA PARATYPHI OR TYPHI 
  CASE DEFINITION
DEFINITE AFI + Blood culture positive for S.Typhi or S.Paratyphi 
  AFI + Typhidot (IgM) positive + other serologies negative 
  AFI + Fourfold rise in titre on the WIDAL 
  
 
SPOTTED FEVER 
  CASE DEFINITION
DEFINITE AFI + Rash+ Spotted Fever IgM ELISA positive + other serologies 
negative 
-OTHER 
RICKETSIOSIS 
AFI + Rash+ OXK19 positive + skin biopsy suggestive of 
Rickettsial vasculitis 
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LEPTOSPIROSIS 
  CASE DEFINITION
DEFINITE AFI + 1st Leptospira IgM ELISA negative followed by a positive test 
on convalescent sera 
PROBABLE AFI + Leptospira IgM positive + all other serologies negative 
 
DENGUE FEVER/ HEMORRHAGIC FEVER/ SHOCK SYNDROME/ 
  CASE DEFINITION  
DEFINITE AFI + Dengue IgM positive + other 
serologies negative 
 
  AFI + Dengue IgM negative + Dengue 
IgM or IgG positive on convalescent 
sera 
A case was diagnosed as Hemorrhagic Fever if there was presence of 
thrombocytopenia + coagulopathy + features of hemorrhage 
A case was diagnosed as Shock Syndrome if there was presence of Shock (BP < 
90mmHg) + other features of DHF
PROBABLE 
 
AFI + All serologies positive + Clinical 
features compatible with a diagnosis of 
Dengue Hemorrhagic Fever 
Thrombocytopenia (100 000 cells or less per 
mm3) 
And evidence of plasma leakage due to 
increased vascular permeability, 
manifested by one or more of the following: 
• ≥20% rise in average hematocrit for age and 
sex + hypoalbuminemia + effusions 
  
Plus 
-       Positive tourniquet test 
-       OR 
-       Bleeding: mucosa, gastrointestinal 
tract, injection sites or other 
hematemesis or melena 
  
 
 
 
Acute undifferentiated febrile illness was defined as an undefined case of fever after the 
above work was negative. 
*Febrile serology: scrub typhus IgM ELISA (Scrub Typhus DetectTM, Inbios 
International Inc, Seattle, USA); Qualitative assays: Leptospira IgM ELISA (SD 
Leptospira IgM, Standard Diagnostics Inc, Kyonggi-do, Korea),  Typhidot [IgM and IgG] 
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(Test-itTM , Life Assay Diagnostics Ltd, Cape Town, South Africa); Rapid assay: Dengue 
IgM-IgG ELISA (Dengue Duo Cassette, PanBio Ltd). Spotted fever IgM ELISA (PanBio 
Ltd) was done for patients with rash when indicated. 
Acute Kidney Injury 
AKI was defined by RIFLE criteria using the definitions summarized in Figure 3 and 
Table 2 respectively. Urine output was not used in the study design owing to inability to 
monitor and measure of hourly urine output or factor unanticipated diuretic use. 
(64)(65)Whenever a baseline creatinine was not available it was derived using the 
abbreviated MDRD equation assuming a baseline GFR of 90 ml/min/1,73 sq m. A similar 
approach was used to calculate RIFLE based on Cystatin C GFR using the Grubb 
equation and deriving a baseline Cystatin C. 
Serum creatinine was measured using the modified Jaffe’s kinetic alkaline picrate method 
using an automated analyzer Olympus AU 2700 (Japan) 
Cystatin C was measured by particle enhanced immunoturbidimetry. 
Liano score 
Severity of illness at admission was standardized using the Liano score, measured by the 
formula (0.032 * age in decades - 0.086 * male gender - 0.109 * nephrotoxic medications 
+ 0.109 * oliguria + 0.116 * hypotension + 0.122 * jaundice + 0.150 * coma - 0.154 * 
consciousness + 0.182 * assisted respiration + 0.210). Oliguria was defined as urine 
output less than 400 ml /day, hypotension as systolic blood pressure less than 100 mm for 
8 hours with or without ionotropes, jaundice as total bilirubin more than 2 mg % and 
GCS equal to or less than equal to 5. 
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Systemic Inflammatory Response Syndrome (SIRS) 
SIRS was defined as presence of two or more of temperature more than 38 or less than 36 
°C, heart rate more than  90 / min, respiratory rate more than 20/min and leucocyte count 
more than 12000/ cu mm or less than 4000/ cu mm or 10% band forms.(85) 
FENa Interpretation 
Fractional excretion of sodium (FENa) was calculated using simultaneous urine and 
serum samples for sodium and creatinine at recruitment and applying the formula: (Urine 
Na * Serum Creatinine) / (Urine creatinine * Serum Na) 
ATN was interpreted as FENa > 2 and pre renal AKI as FENa < 1. (86)  
Renal Failure Index 
Renal failure index (RFI) was calculated using the formula: Urine sodium * (Plasma 
creatinine / Urine creatinine) and was interpreted as ATN if RFI > 2 and pre renal AKI if 
RFI  < 1. 
End Points 
The primary end points were death during in hospital stay or recovery of renal function at 
discharge. 
Patient data was collected by the primary investigator from the patient and from hospital 
records. Demographic data was obtained from hospital records and laboratory data from 
the hospital electronic laboratory database.  
 
 
 
 
 38
Results 
Recruitment and categorization of patients according to disease etiology is summarized. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion criteria: Inpatient, age more 16 years, fever duration 5-21 days. 
Exclusion criteria: Localized infection, HIV infection, autoimmune infection malignancies. 
History & Clinical Evaluation. 
Informed consent. 
Investigation: Complete blood counts, blood film for malarial parasite, serial creatinine, 
electrolytes, liver function tests, blood culture, chest x ray, urinalysis, ultrasound abdomen 
when required. 
Patients consenting for participation in the study n = 163 
Patients with exclusion criteria after investigations n = 136 
Malaria smear 
positive n = 25 
Blood culture proven  
S typhi n= 9 
Blood Culture Negative 
Scrub Typhus  
n = 65 
Dengue Fever  
n = 15 
Serology Screen 
 
AKI :  n = 97 (71.3%) 
Death: n = 36 (26.5%) 
Leptospirosis   
n = 2 
Undifferentiated   
n = 19 
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Baseline Characteristics 
Demographics 
163 patients were enrolled in the study for evaluation after admission. Of these patients 
27 patients were excluded as they were subsequently diagnosed to have localized 
infections including microfilarial infection, tuberculosis, viral meningoencephalitis, 
vasculitis, pneumonia, HIV infection, urosepsis, thrombotic thrombocytopenic purpura, 
H1N1 infection, post partum sepsis or bacteremia and heatstroke. 136 patients were 
included for final analysis in the study. The mean age was 40.9 ± 15.6 (16 to 77 years) 
with a sex ratio 2:1 (male 91: female 45). The patients predominantly belonged to the 
states of Tamil Nadu and Andhra Pradesh, with a mean distance from the hospital of 76.7 
km (5 to 557 km). 95.6% patients were admitted from the emergency room (ER).  
 
Clinical Presentation 
Prior to admission at our institution 78 (57.4%) patients visited a local physician and 
received treatment; however the nature of treatment and medications received were often 
not known. 52.2% of the patients received medications prior to admission, of whom the 
use of antibiotic could be confirmed in 29 (21.3%), aminoglycosides in 2 (1.5%), 
NSAIDS in 6 (4.4%) and anti malarials in 5 patients (3.7%). Medications taken by the 48 
(35.3%) patients could not be identified. (Figure 8)  
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Table 5. Baseline Investigations. 
Mean hemoglobin (Hb) 11.9 ± 2.6 gm/dL 
Total leucocyte count (TLC) 12211 ± 8682.7 /cu mm 
Platelet (plt) count 99 ± 180 x 109 /L 
Prothrombin Time  (PT) 14.7 ± 4.8 secs 
Serum creatinine (creat) 2.5 ± 2.4 mg/dL 
Serum sodium (Na+) 132 ± 6 mEq/L 
Serum potassium (K+) 4.2 ± 0.8 mEq/L 
Serum bicarbonate (HCO3-) 16.6 ± 6.5 mEq/L 
Total bilirubin (TB) 3.8 ± 6.2 mg/dL 
Direct bilirubin (DB) 2.7 ± 5.4 mg/dL 
Serum albumin (alb) 2.9 ± 1.7 gm/dL 
Aspartate aminotransferase (AST) 234 ± 758 U/L 
Alanine amintransferase (ALT) 107 ± 246 U/L. 
 
Table 6. Baseline Arterial Blood Gas Values. 
pH 7.32 ± 0.1, 
pCO2 29.1 ± 6.9 mm Hg 
pO2 114 ± 66.9 mm Hg 
HCO3 19.1 ± 19.2 mEq/L 
Base excess (ABE) - 9.6 ± 6.2  mmol/L 
Lactate (lac) 4.7 ± 4.2 mmol/L 
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Table 7. RIFLE Staging. 
RIFLE GRADE No AKI Risk Injury Failure 
RIFLE Creat 54 (39.7%) 14(10.3%) 19 (14%) 49 (36%) 
RIFLE GFR 39 (28.7%) 27 (19.9) 25 (18.4%) 45 (33.1%) 
RIFLE Final 39 (28.7%) 27(19.9%) 21(15.4%) 49(36%) 
 
AKI vs non AKI. 
Comparison of the groups by RIFLE categorization is depicted in table (Table 8) 
 
Table 8. Non AKI vs AKI patients comparison. 
 No AKI Risk Injury Failure p 
Distance from 
Vellore (Km) 
97.2±94.5 77.5±116 57.9±70.1 117±27.7 0.607 
Duration fever 
(days) 
8.1±2.9 8.4±3.8 7.2±2.9 8±4.1 0.712 
Hospital Stay (days) 6.1±3.2 7.1±5.5 6.2±3.2 8.9±6.3 0.049 
Ionotropes 
requirement (n,%) 
5 (12.8%) 7 (25.9%) 5 (23.8%) 29(59.2%) < 0.001 
Ventilation 
requirement (n,%) 
8(20.5%) 7 (25.9%) 8 (38.1%) 25 (51%) 0.043 
Transfusion 
requirement (n, %) 
6 (15.4%) 2 (7.4%) 4 (19%) 19(38.8%) 0.007 
Dialysis 
requirement (n, %) 
- - 1 (4.8%) 24 (49%) < 0.001 
Survivors:Dialysis 
(n,%) 
- - - 9 (7.5%) 0.444 
Death (n,%) 4 (10.3%) 2 (7.4%) 6 (28.6%) 24 (49%) < 0.001 
 
 46
The mean age of patients with AKI was higher (44.5 ± 15.2 vs 32.1 ± 13 yrs, p < 0.001) 
as were the admission severity scores using the Liano score (0.4 ± 0.2 vs 0.3 ± 0.2, p = 
0.002).  Patients in the R, I and F had prolonged hospital stay and progressively worse 
outcomes and organ support progressing from R to F. Similarly mortality and dialysis 
requirement had an incremental trend with increased requirement and mortality in the 
intensive care unit (ICU) and high dependency unit (HDU). 
 
AKI in Elderly with AFI. 
14 elderly patients were studied for outcomes. (Table 9) 
 
Table 9. AKI in elderly. 
 Age < 65 yrs Age ≥ 65 yrs p 
No AKI (n,%) 39 (32%) - - 
Risk (n,%) 27 (22.1%) - - 
Injury (n,%) 16 (13.1%) 5 (35.7%) 0.002 
Failure (n,%) 40 (32.8%) 9 (64.3) 0.002 
Dialysis (n,%) 22 (18%) 3 (21.4%) < 0.001 
Death (n,%) 29 (23.8%) 7 (50%) < 0.001 
 
All the elderly patients ie age ≥ 65 years (n=14/136) had AKI with I in 35.7% and F in 
64.3% respectively (p=0.002).Dialysis requirement (3/14, 21.4%, p < 0.001) as well as 
death (7/14, 50%, p  < 0.001) was high in this group.  
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RIFLE criteria and AKI in AFI. 
AKI at admission was established in 87 patients (R-26, I-21 and F-40) with subsequent 
worsening noticed from R to I in 3 and I to F in 6 patients (shaded area) . Of the 48 
(35.6%) patients without AKI at admission 4 progressed to R, 3 to I and 3 to F during the 
hospital stay and these 10 patients (red box) could be referred to having hospital 
associated AKI (p < 0.001). (Table 8)  
 
Table 10. Shift of RIFLE class post admission. 
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N (%) No AKI Risk Injury Failure Total 
No AKI 38 (100) 4 (14.8) 3 (14.3) 3 (6.1) 48 (35.6) 
Risk - 23 (85.2) 3 (14.3) - 26 (19.3) 
Injury - - 15 (71.4) 6 (12.2) 21 (15.6) 
Failure - - - 40 (81.6) 40 (29.6) 
Total 38 (28.1) 27 (20) 21 (15.6) 49 (36.3) 135 (100) 
 
 
An improvement in the RIFLE grading from F to I in 6, F to R in 7, F to no AKI in 9, I to 
R in 4, I to no AKI in 9 and from R to normal renal function in 20 patients (shaded area) 
was noted. (Table 9) 
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Heparin free dialysis was done for 72% patients predominantly in the ICU. Slow Low 
Efficiency Dialysis (SLED) was done in 48 % patients, who were hemodynamically 
unstable and mortality of those who underwent SLED was 100%. Patients who were 
hypotensive at admission and required ionotropic or ventilatory support also had poor 
outcomes. 18 (72%) patients who underwent dialysis were admitted to the ICU or HDU 
of whom 4 (16%) survived, while in the ward 5 out of 7 (71.4%) survived (Table 12).  
 
Table 12. Dialysis non survivors vs survivors. 
 Non Survivors n=16 Survivors n=9 p 
Males (n,%) 11 (44%) 9 (36%) 0.061 
Mean Age (in years) 46.8 ± 14.8 30.9 ± 10.9 0.010 
Oliguria (n,%) 12 (48%) 7 (28%) 0.396 
Mean MAP (mm Hg) 74 ± 25.9 90.4 ± 17.8 0.109 
Mean Creatinine (mg/dL) 4 ± 2.1 7.5 ± 3.8 0.006 
SIRS (n,%) 15 (93.8%) 8 (88.9%) 0.667 
Altered Sensorium (n,%) 11 (44%) 2 (8%) 0.004 
Ventilation (n,%) 13 (52%) 2 (8%) 0.004 
Ionotropes (n,%) 14 (56%) 2 (8%) 0.001 
SLED (n,%) 12 (48%) -   < 0.001 
Heparin Free (n,%) 12 (48%) 4 (16%) 0.192 
Admission: Ward (n,%) 2 (8%) 5 (20%) 0.049 
HDU / ICU (n,%) 14 (56%) 4(16%) 0.049 
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A mean of 2.9 ± 2 sessions (1 to 8 sessions) for 2.9 days (0 to 12 days) was done with no 
significant difference in duration between survivors and non survivors while on dialysis ( 
2.8 vs 3.1 days). The nine patients who survived after dialysis to discharge, with 
improvement of renal function, had a mean discharge creatinine of 2.6 ± 1.5 mg/dL 
(creatinine values: 1.2, 1.2, 1.2, 1.7, 1.9, 2.8, 4, 4.5 and 4.9 mg/dL). None of them 
underwent dialysis after discharge. The mean age of this survival group (30.9 ± 10.9 vs 
46.8 ± 14.8 yrs, p = 0.01) compared favorably to those who died. Other baseline 
parameters were not significantly different across both groups of patients. Of note was 
the fact that patients who survived had a higher mean creatinine at admission (7.5 ± 3.8 
vs 4 + 2.1 mg/dL, p = 0.006) and comparatively less multi organ dysfunction.  
 
Disease Etiology 
Scrub Typhus 
Scrub typhus was the most common diagnosis in 47.8% patients. 95.4% presented with 
tachycardia (pulse rate  90/min) and mean pulse rate was 106.4 ± 24.7 /min. 98.4% had 
tachypnea (respiratory rate  20 /min) and mean respiratory rate was 29 ± 9.2 /min.  
Oliguria was observed in 30.8% patients.  
When patients with scrub typhus were compared to those with other etiologies ie malaria, 
dengue fever, typhoid, spotted fever and undifferentiated fever, the former had less 
coagulopathy (PT 13.4 ± 3.6 vs 15.7 ± 5.5 secs, p = 0.030) and milder hyperbilirubinemia 
(2.3± 2.6 vs 5.2 ± 8mg/dL, p = 0.007).  Lower FENa (2.3 ± 2.7 vs 6.4 ± 10, p = 0.005) as 
well as RFI (3 ± 3.2 vs 8.2 ± 13.5, p = 0.006) was noted. 
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Incidence of AKI was comparable across both groups (69.2 vs 53.6%, p = 0.4) with R (20 
vs 19.7%), I (16.9 vs 14.1%) and F (32.3 vs 39.4%) as were the dialysis requirement (32 
vs 68%, p = 0.080) and mortality (21.5 vs 31%, p = 0.212). 
 
 Malaria 
Malaria was the diagnosed in 18.4% patients constituted by mixed malarial infection in 
13.2%, P. vivax in 3.7% and P. falciparum in 1.5%. Tachycardia was observed in 80% 
with mean pulse rate 104.4 ± 15.7 /min. Oliguria was observed in 32% patients. 
Splenomegaly (48 vs 14.8%, p  0.001) was commonly observed when compared to non 
malarial patients.  
When baseline investigations of malarial and non malarial patients were compared they 
had worse anemia (10.6 ± 2.9 vs 12.2 ± 2.5 gm/dL, p = 0.005) and hypoalbuminemia (2.6 
± 0.5 vs 3 ± 0.7gm/dL, p = 0.023) and hyperbilirubinemia (10.5 ± 10.5 vs 2.3 ± 3.2 
mg/dL, p < 0.001). Incidence of AKI was not different across the groups (64 vs 73%, 
p=0.4) with R (16 vs 20.7%), I (8 vs 17.1 %) and F (40 % vs 35.1%).  
Their mean hospital stay, dialysis requirement as well as mortality were not significantly 
different. However, among patients who required dialysis the mortality was higher (80 vs 
10%, p < 0.001) in the malaria group.  
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Dengue Fever. 
Dengue including hemorrhagic fever was diagnosed in 11% patients. At clinical 
presentation tachycardia was observed in 61.5% with mean pulse rate 102.5 ± 21.3 / min. 
Oliguria was observed in 21.4 %. 
When baseline investigations of patients with dengue were compared with fever of other 
etiologies transaminitis (AST 942.9 ± 2192 vs 145.7 ± 141 U/L, p < 0.001; ALT 346.9 ± 
682 vs 76.9 ± 69.5 U/L, p < 0.001), higher FENa (8.4 ± 17.2 vs 3.7 ± 5.3, p = 0.051) as 
well as RFI (11.6 ± 23.8 vs 4.8 ± 7.1, p = 0.036) was observed. AKI was seen in 60% 
with R (13.3 vs 20.7%), I (20 vs 14.9 %) and F (26.7 % vs 37.2%) compared to the non 
dengue group.  
The mean hospital stay (7.3 ± 5 vs 7.3 ± 5.1 days, p = 0.900), blood and related products 
transfusions (40 vs 20.7%, p = 0.092), dialysis requirement (26.7 vs 17.4 %, p = 0.400) 
and mortality (33.3 vs 25.6%, p = 0.500) was comparable. However in those requiring 
dialysis the mortality was higher (80 vs 10%, p < 0.001).  
Typhoid Fever 
Typhoid was diagnosed in 6.6% patients. When compared to patients with other 
etiologies they presented with diarrhea (55.6% vs 13.7, p= 0.001) and dehydration (88.9 
vs 56.5%, p = 0.056). Overall they compared to non typhoid patients in the study except 
more severe hypoalbuminemia (2.9 ± 0.7 vs 3.3 ± 0.8, p = 0.051). Admission creatinine 
(2.2 ± 1.9 vs 2.6 ± 2.5 mg/dL), FENa (1.36 ± 1.5 vs 4.37 ± 1.4, p = 0.3) and RFI (1.7 ± 
1.8 vs 5.7 ± 10.1, p = 0.3) were comparable. 
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AKI was seen in 66.7% patients of whom R was present in 44.4% and F in 22.2%. 
Ionotropic support was required in one patient and hemodialysis in two patients, both of 
whom succumbed to their illness. 
Leptospirosis 
Leptospirosis was seen in two patients both of whom had AKI, one each in the R and F 
categories. The creatinine at admission was 3.8 ± 3.5 mg/dL with GFR 28.3 ± 26.8 
ml/min. They did not differ significantly when compared with patients who did not have 
leptospirosis.. Both patients improved at discharge without requirement of dialysis. 
Undifferentiated Fever 
When undifferentiated fevers were segregated from the group of confirmed fevers and 
compared, they presented with increased incidence of systemic features like tachypnea 
(82.4 vs 56.5%, p = 0.040), hypotension (25 vs 18.4%, p =0.5) and oliguria (52.9 vs 
29.3%, p = 0.8). Few diagnostic clues were seen on clinical examination.  
Baseline investigations showed normal platelets (3.68 vs 0.78 lacs/cu mm, p < 0.001), 
coagulopathy (PT 19.6 ± 6.6 vs 13.6 ± 3.7 secs, p < 0.001),  hypoalbuminemia (3.3 ± 0.6 
vs 2.9 ± 0.7 mg/dL, p = 0.006), increased proteinuria  ( UP/UC 2.6 ± 3.5 vs 1.1 ± 1.2, p =  
0.002),  higher FENa (9.3.± 8.8, 3.6 ± 6.9, p = 0.012) and RFI (13.2 ± 12.6 vs 4.6 ± 9.2,  
p = 0.005).  
AKI was commonly observed (94.7% vs 67.5, p = 0.010) with significantly more patients 
in the in I and F grades. AKI split as R (10.5 vs 21.4%), I (26.3 vs 13.7%) and F (57.9 vs 
32.1%) was significantly more in the undifferentiated group (p = 0.020).  
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The mean hospital stay was comparable (6.6 ± 5.5 vs 7.4 ± 5.1 days, p = 0. 508) but this 
was influenced by early deaths during hospital stay. They had higher ionotropic support 
requirement (63.2 vs 29.1%, p = 0.004) and admission to the ICU or HDU (78.4 vs 
36.8%, p = 0.023).Mortality was higher in this group (56.2 vs 22.2%, p = 0.010). For the 
patients with available data the CPK, LDH, amylase, lipase and procalcitonin levels were 
not significantly different across the groups. 
Summary AFI in AKI 
Falciparum malaria had the highest incidence of AKI (100%). Undifferentiated fevers 
had the highest dialysis requirement (26.3%) and mortality (52.6%). In the differentiated 
fevers dialysis requirement was highest in the mixed malarial infection (27.8%) and 
mortality in dengue fever (42.7%). (Table 13) In the patients who died multi organ 
dysfunction with higher baseline Liano scores was noticed. Requirement of organ support 
in terms of dialysis, ventilatory and ionotropic support predicted poor outcomes. 
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Table 13. AFI etiology and AKI. 
AFI etiology (n,%) No AKI Risk Injury Failure AKI (%) 
Scrub typhus  20 (30.8) 13 (20) 11 (16.9) 21 (32.3) 69.2% 
Malaria: Mixed  20 (33.3) 13 (11.1) 11 (11.1) 21 (44.4) 66.7% 
Malaria : Falciparum - 1 (50) - 1 (50) 100% 
Malaria: Vivax  3 (60) 1 (20) - 1 (20) 40% 
Dengue fever  5 (41.7) 1 (8.3) 2 (25) 3 (25) 58.3% 
Dengue: Hemorrhagic  1 (33.3) 1 (33.3) - 1 (33.3) 66.7% 
Typhoid  3 (33.3) 4 (44.4) - 2 (22.2) 66.7% 
Leptospirosis  - 1 (50) - 1 (50) 100% 
Undifferentiated  1 (5.3) 2 (10.5) 5 (26.3) 11 (57.9) 94.7% 
 
Urinary Indices in AKI 
The mean specific gravity was 1.019 ± 0.006, pH 6.07 ± 0.62, RBCs 13.3 ± 22.0 /HPF 
and WBCs 7.9 ± 16.4 /HPF. The urine spot sodium was 88.8 ± 51.4 with FeNa 4.2 ± 7.2 
meq/dL and UP/UC 1.28 ± 1.8. Mean urine spot potassium was 23 ± 14.6 mEq/dL and no 
evidence of wasting. The urinary indices are compiled in Table 14. 
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Table 14. Urinary Indices in AFI based on etiology. 
Urinary Indices Sp Gravity pH RBCs FeNa UP/UC 
Scrub Typhus 1.012±0.007 5.89±0.52 11.4±19.6 2.3±2.7 1.04±1.1 
Vivax Malaria 1.013±0.003 6 9.3±8.5 4.4±6.9 0.3±0.3 
Falciparum 
Malaria 
1.01 ± 0.000 6 10 14.4 1.7±2.4 
Mixed Malarial 
Infection 
1.008±0.007 6.5 12.7±24.9 5.5±6.7 1.2±1.1 
Dengue Fever 1.007±0.003 6.33±0.52 20.1±30.1 9±18.2 1.4±2.1 
DHF 1.01±0.000 6 13.3±11.5 3 2.3±3.1 
Typhoid 1.010 6 15.1±34.1 1.4±1.5 0.9±1 
Leptospirosis 1.005 6 13 ± 9.9 - 1.1±0.2 
Undifferentiated 1.013±0.008 6.1±0.32 11.7± 9.9 9.3±8.8 2.6±3.5 
Spotted Fever 1.010 7 numerous 0.06 - 
 
Urinary indices in AKI 
 
Comparing the urinary indices in the non AKI vs AKI group RBCs (5.8 ± 7.8 vs 16.3 ± 
24.9, p = 0.020) and FENa (1.5 ± 1.4 vs 5.4 ± 8.5, p = 0.010) were found to be high 
comparatively in the AKI group. In patients who died the FENa was significantly higher 
(7.5 ± 8.2 vs 3.2 ± 6.8, p = 0.013).  
A comparison of the urinary indices in the AKI and non AKI group is shown in Table 15. 
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Table 15. Urinary indices in AKI. 
Urinary 
Indices 
 
Sp Gravity 
 
pH 
 
RBCs 
 
FeNa 
 
UP/UC 
Non AKI 1.011±0.007 6.5±0.97 5.8±7.8 1.5±1.4 0.9±1.37
AKI 1.011±0.006 5.97±0.49 24.9±13.3 5.4±8.5 1.4±1.9 
p 0.946 0.015 0.020 0.011 0.121 
 
Comparing the urinary indices from R across to F in the RIFLE grades FENa (1.39 ± 0.9 
vs 9.1 ± 10.6, p < 0.001) as well as proteinuria (0.6 ± 0.4 and 2.14 ± 2.4, p < 0.001 
respectively) were found to increase. ATN interpreted by FENa > 2 was found in 46.6% 
and pre renal AKI interpreted as FENa  < 1 in 29.1%.  23.9% patients in the AKI group 
had pre renal AKI of whom 13 (40.6%) in R, 9 (40.9%) in I and 3 (8.3%) in F were 
observed. (p = 0.009) ATN was observed in 56.3% in the AKI group with 6 (27.3%) in 
R, 5 (38.5%) in I and 29 (80.6%) in F grades (p = 0.009). 
Cystatin C 
Recruitment mean cystatin C was found to significantly differ in the non AKI and AKI 
groups (1.43 ± 0.41 vs 3.17 ± 2.44, p < 0.001 ) as well as increase across the RIFLE 
grades from R to F (R 1.6 ± 0.30 , I  2.15 ± 0.63 , F  4.45 ± 2.84 , p < 0.001) .The eGFR 
measured by the Grubb equation using Cystatin C and abbreviated MDRD equation using 
creatinine in the sample collected at recruitment differed significantly both in patients 
with AKI ( 26.1 ± 21.8 vs 47.9 ± 46.6 ml/min/1.73 sq m, p < 0.001) and non AKI groups  
(55 ± 24.8 vs 100.1 ± 21.4 ml/min/1.73 sq m, p < 0.001), when the groups were 
categorized on the basis on creatinine 
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When the RIFLE categorization done using Cystatin C was compared with that using 
creatinine, the grades based on Cystatin C were found to differ (p < 0.001). (Table 16)  
 
Table 16. RIFLE comparing creatinine and cystatin C based eGFR. 
 No AKI R I F 
RIFLE creat 39 (28.7%) 27 (19.9%) 21 (15.4%) 49 (36%) 
*RIFLE cystatin c 17 (12.5%) 22 (16.2%) 39 (28.7%) 47 (34.6%) 
* Data from 125 (92%) patients 
The 39 patients in the no AKI group were redistributed as 12 in non AKI, 14 in R, 12 in I 
and 1 in F. Similarly in 25 patients in R based on creatinine 4 were reclassified as no 
AKI, 14 as I and 2 as F. Of the 17 patients in I, 1 was reclassified as R and 7 as F. Of the 
44 patients in F by creatinine 1 was reclassified to no AKI, 2 as R and 4 as I respectively. 
( p < 0.001) (Table 17) 
 
Table 17. RIFLE class shifts using creatinine and Cystatin C based eGFR. 
R
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RIFLE grades using Cystatin C 
Patient No No AKI Risk Injury Failure Total 
No AKI 12 (30.8) 14 (35.9) 12 (30.8) 1 (2.6) 39 (31.2) 
Risk 4 (16) 5 (20) 14 (56) 2 (8) 25 (20) 
Injury   - 1 (5.9) 9 (52.9) 7 (41.2) 17 (13.6) 
Failure 1 (2.3) 2 (4.5) 4 (9.1) 37 (84.1) 44 (35.2) 
Total 17 (13.6) 22 (17.6) 39 (31.2) 47 (37.6) 125 (100) 
* Data from 125 (92%) patients 
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Blood Urea: Creatinine Ratio 
The blood urea : creatinine ratio was not predictive of AKI and no co relation was 
observed with RIFLE scoring. Similarly no information could be derived from its 
analysis for patients who had dialysis or survived to discharge. 
 
Renal Failure Index 
RFI significantly differed in the AKI vs non AKI groups and was found to increase from 
R to F (R 1.8 ± 1.3, I 2.6 ± 2.7, F 12.1 ± 14.6, p < 0.001). It was significantly higher in 
the patients who died (10.5 ± 11.6 vs 4.1 ± 8.9, p = 0.005) and those who required 
dialysis (14.7 ± 18.1 vs 3.7 ± 6.1, p < 0.001).  
 
Scoring Systems 
Both the Liano score as well as the Vellore score to predict mortality at admission were 
high at 0.40 ± 0.2 and Vellore score 0.97 ± 0.1. Liano scores in patients who developed 
AKI (0.43 ± 0.2 vs 0.33 ± 0.2, p < 0.001) as well as those who died (0.51 ± 0.2 vs 0.36 ± 
0.2, p < 0.001) were higher. The Vellore score did not significantly differentiate between 
these groups. 
Management 
Treatment with doxycycline in 86.1% patients, often empirically at admission while 
awaiting the febrile illness work up, was observed and addition of antibiotics based on 
the suspected underlying etiology. Organ support was required in the form of invasive 
ventilation in 35.3%, ionotropes in 33.8% and hemodialysis in 18.4%. Diuretics were 
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used in 13.2%. Blood and product transfusion was required in 22.8% patients. Patients 
requiring ionotropes, blood or product transfusion, ventilation and dialysis were at high 
risk for mortality (p < 0.001) 
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Discussion 
Baseline Characteristics 
Epidemiologically AKI is commoner in males, 67% in our study compared to 64% in a 
multinational study.(87) Increasing age, severity of illness and greater distance from 
centers of care are associated with higher mortality in AKI and a similar association was 
seen for age and severity of illness in our study. (88)  
AFI and AKI 
AKI was found in 71.3% of our patients with R, I and F as 19.9%, 15.4% and 36% 
respectively and mortality of 30.9%. Using FENa as a marker for pre renal AKI, FENa < 
1 was observed in 30%, 16.7% and 10% in R, I and F respectively suggesting a 
possibility of recovery with early management which decreases with progression from R 
to F.  In most cases the group in R represents volume responsive hypovolemia and is 
managed effectively with fluids and ionotropes. However this benefit is not extended to 
late initiation of volume replacement and restoration of renal perfusion.(89)  
Early AKI diagnosis has better outcomes as compared to late AKI.(69) Mortality in R 
(0%), I (0%) and F (12.5%) for admission to wards compared favorably to R (50%), I 
(100%) and F (84%) in the MHDU/ICU patients, who predominantly presented with 
established multi organ dysfunction. A multi center study in Brazil on AKI in ICU, with 
sepsis as the main etiology, showed 71% mortality with distribution in RIFLE grading R 
(28%), I (24%) and F (48%) indicating high incidence of AKI and death in ICU care.(90) 
Distance of travel for treatment did not affect outcomes probably related to a referral 
bias, whereby sick patients at high risk for mortality were referred for admission 
irrespective of distances. Although their duration of fever was comparable, patients in 
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RIFLE – F traveled further distances for care reducing the period for early intervention. 
They also had longer duration of hospital stay with high dependency care and organ 
support including ionotropes, invasive ventilation and dialysis. It is noteworthy that 
despite a lower mean age 40.9 ± 15.6 yrs and relatively low co-morbid conditions prior to 
admission the incidence of AKI and death was high. 
 
Mortality in AFI related AKI 
Patients in ICU as well as those transferred to the wards after ICU care were at higher 
risk for death.(91) Death was common in ICU in the non AKI group in high dependency 
care as well indicating multi organ dysfunction as a poor prognostic indicator for survival 
in AFI. A recent study supports the theory that the severity of illness confers an increased 
risk, putting those who develop AKI or at risk of AKI as a result of their illness at risk for 
death.(92) In our study patients who presented in SIRS were at higher risk of death in the 
presence of AKI as compared to those without AKI (32.5 vs 11.4%, p = 0.013). 
A rise of serum creatinine by as much as 0.3 mg/dL increases the risk of death (93), 
evidenced by high death rates across from R to F. This has been recognized by AKIN in 
an attempt to improve the RIFLE criteria by using this 0.3 mg/dL rise to label Stage I 
AKI. Comparison of AKIN and RIFLE staging and outcomes were not assessed in this 
study but based on available evidence results are comparable for both.(74) 
Dialysis uniformly had poor outcomes with SLED being the predominant modality of 
renal replacement in ICU patients owing to hemodynamic instability. When to initiate 
dialysis and how much continues to be debated. Early and more dialysis in terms of 
frequency (94) and intensity (95) as proposed earlier has been recently addressed with no 
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beneficial effects observed when compared to thrice a week intermittent hemodialysis or 
CRRT at 20 ml/hour. (96) Our policy is to offer hemodialysis based on standard 
indications for dialysis. 
 
Death in AFI related AKI  
Our incidence of AKI and death in AFI is high owing to a referral bias and triage in the 
emergency room (ER) by a specialized medical team. This team ensured early 
management and stabilization, often with short ER stay less than 24 hours in the ER of 
many patients, thus selecting a higher number of patients with SIRS and MODS for 
admission. This may explain the difference compared to an earlier study showing AKI to 
be 42.1 %.(5) 31.1% of our study population was managed in the HDU and ICU during 
hospitalization with 51.5 % patients in these areas having AKI, dialysis requirement in 
72% and 78 % mortality.  
Outcomes of dialysis in AFI related AKI 
Dialysis was necessitated for care of AKI in 18.4% in our study. Dialysis requirement in 
AFI has poor outcomes with and overall mortality of 64% in our study. ICU mortality in 
patients undergoing dialysis was 77.8%. Recent literature (21) demonstrates a major 
epidemiological shift in management of AKI from the wards to ICUs. It has major 
ramifications on health care allocation and cost of ICU care which is beyond the reach of 
most patients in India. The period of hemodialysis is prone to infection, 90% in an ICU 
study from Belgium, which however does not contribute to mortality. (97) 
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It is interesting to note that 36% patients who survived to discharge after hemodialysis 
did not touch baseline in most cases at the time of discharge. In the absence of follow up, 
progression to CKD could not be estimated. There is immense concern on a nexus 
between AKI, CKD and dialysis dependence. Progression to CKD post AKI is 
characterized by hyperfiltration, microalbuminuria and hypertension. (98) 6% of these 
patients are known to progress to ESRD within two years. (99)  About 25% of the 
increase in incidence of ESRD in the USRDS has been attributed to AKI (100) and 
considering high incidence of AFI in India, the incremental burden of CKD as a result of 
AKI in ARF in the years to come is likely to be very high. 
Early intervention for AKI in AFI 
Majority of our patients had contact with a physician at varying stages of their illness 
prior to admission at our center. Awareness amongst physicians, who first manage AFI at 
the community level of a possibility of AKI in AFI, thus avoiding nephrotoxic drugs and 
toxins, preventing dehydration and hypovolemic shock and initiation of appropriate 
empirical antibiotics may reduce the percentage of patients who have established AKI 
and tubular injury on first evaluation in tertiary care. Early and aggressive management in 
a tertiary care center with renal triage using RIFLE can direct these resuscitative efforts 
before establishment of renal injury and failure. Recognizing AKI as an expression of 
sepsis and managing sepsis effectively and early may reduce AKI incidence. Although 
our study excluded patients with CKD, factoring them for early triage and ensuring least 
insult to an already compromised kidney at high risk for irreversible damage and dialysis 
dependence is imperative. 
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AFI etiology and AKI 
Scrub typhus had a high incidence of AKI (69.2%) and complete recovery in 50% of 
these. In an earlier study on scrub typhus shock, altered sensorium, ARDS and metabolic 
acidosis and AKI were poor prognostic markers. AKI defined as creatinine more than 1.4 
has been observed in about 20% patients . (101) Use of RIFLE criteria as in our study 
could explain the higher incidence as well as earlier identification of AKI in patients with 
AFI. An early and dramatic response to doxicycline and IV fluid supplementation in the 
ER was found with a remarkable role in preventing organ dysfunction and death. Careful 
examination of an eschar observed in 44.6% compared to 45.5% in the earlier study, is a 
useful clinical clue to direct early management pending diagnostic serology.(101) 
 
Prognosis using Liano score in AFI related AKI 
Prediction of AKI and death at admission is important for responsible fiscal allocation of 
limited hospital and ICU care in India. The BEST ( Beginning and Ending Supportive 
Therapy for the Kidney) study for Mortality Prediction Models (MPM) including the 
Mehta, Paganini, Chertow and Liano models showed ROCs ranging from 0.6 for 
Chertow to 0.7 for Liano  scoring.(87) The mean Liano score was high in our study (0.4 ± 
0.2). In patients who developed AKI or died the Liano score was significantly higher. It 
could be used as a tool to prioritize access to limited ICU care, but all MPM s studied till 
date have shown sub optimal discrimination as robust predictors of mortality.(90) 
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RIFLE criteria and prediction of mortality in AFI 
RIFLE classification provides a clear trend in increasing mortality from R (7.4%), I 
(28.6%) and F (49%) in our study. This trend has been noticed with varying degrees in all 
studies most of which are done exclusively in critically ill patients admitted to ICU 
patients. (69) Class shifts from no AKI to AKI and across risk to injury to failure, at 
every level were found to have increasing dialysis requirement and mortality. (5) Hospital 
associated AKI was low in our study owing to established AKI at admission in most 
patients and effective interventions once admitted to the ER reducing progreson once 
admitted to the hospital. 
In a study by Uchino S, et al of 20126 general admissions to hospitals with 14.7% ICU 
admissions, mortality was R (15.1%), I (29.2%) and F (41.1%). Multivariate analysis 
showed RIFLE to be a predictor for hospital mortality with linear increase in odds ratio 
from Risk to Failure.(72) Patients with delayed AKI presenting in sepsis and hypotension 
require mechanical ventilation and have a higher mortality. (102) AKI in AFI across the 
spectrum of RIFLE increases the risk of death. Late presentation with sepsis and AKI 
explain the high mortality in our study. 
Primary involvement and secondary involvement of the kidney in multiorgan dysfunction 
continues to be studied. Early AKI and progression result in salt retention, fluid overload, 
hyperkalemia and metabolic acidosis and consequently hypotension, impaired organ 
perfusion, insulin resistance, protein catabolism, anemia and infection arising out of 
impaired innate immunity. This spectrum was commonly observed in our patients. The 
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kidney in animal models has shown to stimulate a systemic pro inflammatory response as 
a result of ischemia- reperfusion injury often manifesting as ARDS. (69) 
Limitations of RIFLE classification: Early predictors of AKI in AFI 
Despite its utility RIFLE does not provide functional information on the nature of AKI. 
In this context previous established but relatively less used indices like FENa are useful 
adjuncts to management. 13/32 (43.3%) patients had pre renal using FENa in the no AKI 
group and these could represent a population with ongoing renal damage undetected by 
RIFLE who could benefit from early intervention. This also may be a case for use of 
biomarkers to detect AKI earlier. Despite its limitations FENa continues to be a useful 
tool in identifying patients in early AKI and used in conjunction with RIFLE may be 
effective in reversing AKI and preventing progression after admission. As a cheap and 
easily available tool it could effectively reduce costs and promote management at local 
centers with volume repletion by the primary physician. 
Cystatin C using the Grubb equation showed lower GFR compared to the creatinine 
based abbreviated MDRD equation. RIFLE grading using the Grubb GFR showed 
increased severity of AKI. This may be a case for using admission Cystatin C as a 
biomarker of AKI. Cystatin C predates detection of AKI by two days compared to 
creatinine with high diagnostic accuracy (103) and could differentiate presentations in pre 
renal azotemia and AKI. The future of AKI management could be revolutionized by 
availability of newer biomarkers for early diagnosis. 
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Limitations of study 
This study was done in a tertiary referral center and the patients may not be 
representative of other centers where the case mix and referral patterns may be different. 
It used creatinine and GFR criteria for interpretation of RIFLE, excluding the urine 
output criteria. A true baseline as recommended by the ADQI was unknown for all 
patients and the calculated baseline from the MDRD equation using a baseline eGFR of 
90 ml/min which may have led to a greater estimate of change and consequently higher 
estimation of AKI. Although the RIFLE using MDRD equation with a baseline of 90 
ml/min/1.73 sq m is validated recently in this group of patients it remains a substitute for 
actual GFR. Using a lower cut off as per the ADQI recommended baseline of GFR of 75 
ml/min, reduced the AKI in terms of numbers but the trends in classification and related 
morbidity and mortality held true. 
Lastly there was limited follow-up after hospital discharge and no data to assess recovery 
and progression to CKD over a time frame.  
The study also did not use novel biomarkers of kidney function to further delineate 
etiology and predict early renal dysfunction. 
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Summary  
1. In this study of AKI in tropical AFI inpatients at a tertiary care hospital had a high 
incidence of AKI (71.3%) and death (26.5%). 
2. Tertiary referral is often late and presentation with SIRS was observed in 84.6% at 
admission. High dependency care was required in 41.2% patients, often for initial 
stabilization and multi organ dysfunction.  
3. AKI was observed at admission in 87 (64%) with 10 (7.4%) patients developing 
hospital associated AKI. 
4. Undifferentiated fever had the highest incidence of AKI (94.7%) with dialysis 
requirement in 26.3% and death in 52.6%.  
5. In differentiated fevers highest AKI was in falciparum malaria (100%) with highest 
dialysis requirement in mixed malarial infection (27.8%) and highest mortality in dengue 
fever (42.7%). Scrub typhus had a good response to treatment. 
6. Promising diagnostic utility of Renal Failure Index, FENa and serum Cystatin C in 
early detection of AKI in AFI. 
7. Grading AKI using RIFLE classification showed risk (R) in 19.9%, injury (I) in 15.4% 
and Failure (F) in 36%. RIFLE was identified as a sensitive tool for diagnosis of AKI in 
AFI and patients have a worse prognosis and outcomes from risk through injury and 
failure stages in terms of organ support, dialysis requirement and death. 
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8. RIFLE criteria using Cystatin C appears to be more sensitive in diagnosing AKI earlier 
and may be a useful adjunct in earlier management. 
9. Liano scoring at admission identifies high risk patients and may be useful for triage to 
high dependency care. 
10. Metabolic acidosis, hyperkalemia, fluid overload and uremia necessitated 
hemodialysis in 18.4% of whom 48% required SLED.  
11. Death in patients initiated on hemodialysis for AKI was high (64%) with 100% 
mortality in those requiring SLED, in view of hemodynamic instability.  
12. Early management of AFI with well directed empirical antibiotic treatment and AKI 
with hydration as well as avoiding nephrotoxic medications improves outcomes. 
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Conclusion 
AKI in AFI is common often requiring multi multispeciality care with dialysis and 
hemodynamic as well as ventilatory support. Mortality is high with shifting trends in 
management from wards to ICUs.  
Severity of AKI in AFI is based on etiology of fever, increasing age, late presentation, 
inappropriate medication use and delayed recognition. 
RIFLE categorization has an incremental risk of adverse outcomes from Risk to Failure 
and helps to detect early AKI and predict unfavorable outcomes, especially in patients 
with multiorgan requirement requiring dialysis and ICU care. 
Cystatin C is an early biomarker and its use improves early detection of AKI as compared 
to creatinine in the RIFLE criteria. 
FENa is a useful, easily available test for early detection of AKI in AFI and its use should 
be encouraged at first contact with a physician to encourage early intervention even at a 
community level. 
Emphasis on prevention and management at the earliest point of contact, particularly the 
community level by educating registered medical practitioners on AFI pattern 
recognition, renal function assessment and early hydration, appropriate antibiotic use, 
avoidance of nephrotoxic drugs, nutrition and early referral to nephrologists for patients 
in AKI will reduce the burden of disease and CKD in the long run. 
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Annexure 1. Informed Consent 
Informed consent 
Study Information 
You are being invited to take part in a study titled “Acute Renal Failure in Acute Febrile 
Illness: Incidence, Prognosis and Outcomes” This study is being done by the departments 
of Nephrology and Medicine at Christian Medical College, Vellore. 
 
You will be examined by doctors in the Nephrology and Medicine department and will be 
asked to undergo pertinent tests which are done as part of routine protocol for any patient 
undergoing evaluation for fever and acute renal failure. No additional tests will be done. 
 
Strict privacy will be maintained during the interview, clinical examination and 
information of laboratory results. Your name will not appear on the study records, but 
will be linked to them by a study number which will be kept confidential by the study 
investigator. This study will not require that you be regularly followed up or be involved 
in any way beyond the time you spend in the hospital for your presenting illness. 
  
Although you are being asked to participate in this study, you are free to decline your 
consent to participate in this study at any time and you will continue to receive treatment 
at Christian Medical College for your illness. 
Please feel free to ask any doubts regarding this study. After understanding all the aspects 
of the study, you may sign below as consent to participation in this study. 
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Consent 
I have been clearly explained in my own language about the proposed study and the 
related investigations to be done thereof, with the understanding that no additional 
charges will be attributed to me in addition to my regular treatment requirement. I 
consent for my blood to be collected, stored and used for diagnostic and research purpose 
for this study or any related research in the future approved by the Institutional Review 
Board. 
  
 
Subject name:      Serial No: 
Hospital number: 
 
 
 
Signature (or thumb impression) of subject/legally acceptable representative: 
Signatory’s name: 
Date:       Serial No. 
 
 
 
Signature (or thumb impression) of subject/legally acceptable witness 
Witness’ name: 
Date:        
 
 
 
Primary Investigator 
Date:       
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Annexure 2. Study Proforma 
Proforma 
Ser No    
Name      Age    Sex 
Co morbid   
Dehydration  Diabetes Mellitus   Hypertension   Coronary Artery Disease 
Nephrotoxic Drugs:  Intake unknown    NSAIDS Aminoglycosides    Radiocontrast 
Duration of fever 
Less than 1 week        1-2 weeks    more than 2 weeks  
Type of Fever 
Continuous  Remittent   Intermittent   
Grade  Low   Intermediate   High 
Chills     Rigors   
Upper Respiratory   
Rhinorrhoea    Throat Pain   Headache 
Lower Respiratory   
Dyspnoea    Cough             Expectoration  Hemoptysis   
Abdominal 
Pain  Vomiting   Diarrhoea  MelenaDistention 
Urinary    
Dysuria Oliguria   Anuria  Hematuria  
Urine output  
CNS    
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Altered Sensorium   Seizures   Focal Defecits  
Musculoskeletal 
Muscular pain  Arthritis  Arthralgia  Myalgia 
Examination 
Pallor  Mild    Moderate    Severe  
Icterus  Cyanosis  Edema  Asterexis  
Skin  Rash   Eschar  Petechia  Purpura 
Pulse Rate  80-100/min     100-120/min     greater than 120/min 
Respiratory Rate  less than 20/min    more than 20/min 
BP    MAP  less than 70   MAP  less than 70  
CVS  S1  S2  S3  Murmurs  
Respiratory   Crepts    Ronchi  
GI  Hepatomegaly  Splenomegaly  Ascitis 
Nervous Concious/Drowzy/Stuporose/Comatose   Focal Defecits 
Musculoskeletal Tenderness  Joint swelling Joint stiffness 
Investigations 
Hb   TLC   DLC   Plat  Film 
PT   PTT   Fibrinogen  Procalcitonin 
BU   Creat   Potassium    HCO3    
TP   Alb   SGOT   SGPT    
Serology  Dengue Leptospira  Typhiod  Scrub 
Malarial parasite    Present /Absent 
USG Kidneys        CXR 
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Urine C/S   Blood C/S   Sputum C/S 
Stool C/S     
Urine R/E   Microscopy     UP/UC 
BBVS     
Transfusions   PC   FFP   PRC 
RIFLE 
Course in hospital 
Day         
Creat         
eGFR         
Urine 
Output 
        
 
Days from onset of fever to renal failure 
Indication for hemodialysis   
Hyperkalemia  Metabolic Acidosis  Anuria  Fluid Overload 
Duration of hemodialysis 
Number of sessions of hemodialysis 
Schedule of hemodialysis  Daily  Intermittent 
Nature of hemodialysis   Regular   SLED 
Hemodialysis Access 
Heparin Schedule:  Saline  Rigid bolus   Rigid Heparin  Systemic    Heparin 
Complications during dialysis 
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Follow up 
Hb   TLC   DLC   Plat 
PT   PTT   Fibrinogen  Procalcitonin 
BU   Creat   Potassium 
HCO3   TP   Alb   SGOT 
USG      CXR 
Time to Recovery 
RIFLE 
Outcome at Discharge:  Recovered  Improving  Death 
 
No Hosp No DiaAge Sex Town Dist AdmDur DiscDurfTypGraPuls Res SIR MAPTem DMHT DrUAGNSA
1 608559D 1 62 1 Kaveripa 63 0 4 1 5 1 2 92 26 1 . 100 0 0 0 0 0
2 613301D 1 42 1 Chitoor  34 2 9 0 14 1 2 86 36 1 117 99 1 0 1 0 0
4 613309D 1 38 1 Chitoor  34 0 7 0 10 1 3 106 32 1 87 98 0 0 0 0 0
5 613360D 1 40 1 Kadapa 248 2 7 0 5 1 1 120 32 1 90 98 0 0 0 0 0
6 613495D 1 65 1 Gudiyata 29 2 2 1 10 1 3 112 22 1 90 98 0 1 0 0 0
7 616102D 1 26 1 Chitoor  34 0 3 0 10 1 1 124 24 1 73 100 0 0 0 0 0
8 081136C 1 29 1 Polur     50 0 2 0 10 1 1 106 28 1 77 103 0 0 0 1 0
9 618110D 1 62 1 Chitoor  34 0 5 0 10 1 2 140 42 1 93 101 1 0 1 0 0
11 616372D 9 31 1 Bankura 1809 0 19 0 5 1 3 112 40 1 70 100 0 0 0 0 0
12 620012D 1 40 1 Tiruvana 77 2 6 0 10 1 1 130 40 1 50 99 0 0 1 0 0
14 620117D 6 46 2 Ranipet 141 1 8 0 15 1 1 98 . 3 93 . 0 0 0 0 0
15 620047D 1 68 2 Somalap. 0 6 0 5 1 1 110 34 1 53 . 1 0 1 0 0
16 620107D 1 50 1 Chittor   34 0 3 0 5 1 1 108 28 1 83 100 1 0 0 0 0
17 616378D 1 51 1 Kadapa 248 0 7 0 15 1 3 84 40 1 100 99 0 0 1 0 0
18 620330D 1 18 2 Chitoor  34 1 14 0 9 1 1 112 44 1 63 . 0 0 0 1 0
19 620377D 6 35 2 Tirupatu 91 2 5 1 7 1 1 110 32 1 67 103 0 0 0 0 0
20 763636A 1 62 1 Vellore  5 2 11 0 10 1 1 114 . 1 83 . 0 1 0 0 0
22 620539D 6 34 1 Chitoor  34 2 3 1 7 1 1 104 44 1 73 100 0 0 0 0 0
23 620470D 1 55 2 Vellore  5 0 4 0 5 1 1 132 40 1 107 103 1 1 0 0 0
24 620462D 1 53 2 Kadapa 248 0 6 0 10 1 1 130 36 1 73 99 0 0 0 0 0
25 620556D 1 21 1 Tiruvana 77 2 9 0 10 1 1 92 28 1 103 102 0 0 0 0 0
28 625048D 3 43 1 Tiruvana 77 0 6 0 7 1 1 104 32 1 83 . 1 0 0 0 0
29 625243D 4 18 1 Tiruvana 77 0 6 0 7 1 1 130 20 1 93 101 0 0 0 0 0
30 625434D 6 23 1 Tiruvana 77 1 17 0 6 1 3 104 . 1 113 . 0 0 0 0 0
31 625413D 1 32 2 Kadapa 248 2 4 1 5 1 1 128 36 1 80 102 0 0 0 0 0
32 625516D 1 54 1 Madanu 35 0 5 0 10 1 1 110 40 1 83 101 0 0 0 0 0
33 625444D 1 20 2 Tiruvana 77 0 3 0 10 1 1 106 28 1 83 103 0 0 0 0 0
34 625692D 3 34 2 Gudiyata 29 2 8 1 10 1 1 128 40 1 80 101 0 0 0 0 0
35 625567D 1 30 1 Ranipet 141 0 6 0 7 1 1 110 44 1 83 104 0 0 0 0 0
36 625550D 1 68 2 Ranipet 141 2 3 1 6 1 1 128 30 1 57 101 0 0 1 0 0
37 630008D 1 25 1 Dharmar 136 1 6 0 10 1 1 104 30 1 80 104 0 0 0 0 0
38 630131D 1 39 1 Sathur   80 2 5 0 7 1 1 120 44 1 57 103 0 0 0 0 0
39 630295D 4 21 1 Vellore  5 2 13 1 14 1 1 152 32 1 80 101 0 0 0 0 0
40 648234D 1 52 1 Walajah 25 0 3 0 5 1 1 98 24 1 73 99 1 0 0 0 0
42 819985C 1 48 2 Chitoor  34 0 5 0 7 1 1 104 24 1 97 101 1 0 0 0 0
43 644390D 6 18 2 Kadapa 248 0 5 0 6 1 1 118 40 1 80 103 0 0 0 0 0
44 651311D 1 55 2 Tiruvana 77 2 13 0 7 1 1 120 24 1 80 100 0 0 0 0 0
45 839020C 3 36 1 Vellore  5 0 3 0 7 1 1 84 18 0 83 . 0 0 0 0 1
46 651470D 1 71 1 Vellore  5 1 6 0 5 1 1 102 28 1 93 98 0 0 0 0 0
48 658142D 4 23 1 Vellore  5 0 7 0 8 1 1 112 28 1 73 102 0 0 0 0 0
49 658185D 6 48 1 Tiruvana 77 2 22 0 3 1 1 0 . 1 0 . 0 0 1 0 0
50 484055C 6 32 2 Chitoor  34 0 1 1 7 1 1 . . 3 . . 0 0 0 0 0
52 667250D 13 35 1 Vellore  5 0 10 0 7 1 1 84 24 3 93 . 0 0 1 0 0
53 669406D 1 21 2 Chitoor  34 0 8 0 5 1 1 160 22 1 73 . 0 0 0 0 0
54 669796D 12 34 2 Chitoor  34 0 27 0 5 1 1 130 44 1 73 101 0 0 1 0 0
56 674066D 6 73 1 Peyad   701 2 4 1 . . . . . 3 . . . . . . .
57 626844D 6 57 1 Vellore  5 2 11 1 15 1 1 106 24 1 103 104 0 1 1 0 0
59 686473D 6 18 1 Chitoor  34 1 8 0 5 1 1 130 40 1 47 1 0 0 1 0 0
63 711029D 4 17 1 Kadapa 248 0 5 0 14 2 1 90 24 1 93 102 0 0 1 0 0
64 714593D 6 39 1 Chitoor  34 1 3 1 4 1 1 132 28 1 90 102 0 0 1 0 0
65 712413D 1 71 2 Vellore  5 2 4 1 7 1 2 136 32 1 103 98 1 0 1 0 0
67 724159D 1 55 2 Vellore  5 2 20 1 5 1 1 116 26 1 77 98 0 0 0 0 0
68 808565C 3 22 1 Vellore  5 0 5 0 5 1 1 100 24 1 93 100 0 0 0 0 0
69 724143D 9 36 1 Chitoor  34 1 4 0 3 1 3 90 24 0 93 100 0 0 0 0 1
70 724402D 13 21 2 Kadapa 248 0 7 0 5 1 1 112 24 1 57 99 0 0 0 0 0
71 730099D 6 40 2 Vellore  5 1 11 0 5 1 3 130 40 1 23 . 0 0 0 0 0
72 265407D 4 54 1 Tirunelve 557 0 14 0 5 1 1 98 24 1 93 101 1 0 0 0 0
73 730129D 1 39 1 Tiruvana 77 0 5 0 10 2 1 120 30 1 83 . 0 0 0 0 0
74 732578D 13 29 1 Vellore  5 0 7 0 10 1 1 100 18 0 90 . 0 0 0 0 0
75 730341D 15 46 1 Tirupatu 91 0 6 0 10 2 1 96 22 0 80 98 0 0 0 0 0
76 730349D 3 22 2 Chitoor  34 0 4 0 5 1 1 82 16 1 83 100 0 0 0 0 1
77 730354D 1 77 1 Vellore  5 0 4 0 8 1 1 92 26 0 107 . 0 0 0 0 0
78 730358D 1 48 1 Gudiyata 29 0 5 0 20 1 1 142 28 1 80 101 0 0 0 0 1
79 724598D 1 52 2 Tirupatu 91 2 11 0 10 1 3 102 24 1 60 103 0 0 0 0 0
80 735043D 15 23 1 Vaniyam 67 0 11 0 6 1 1 98 24 1 83 99 0 0 0 0 0
81 724594D 15 49 1 Chitoor  34 0 8 0 8 1 1 72 20 0 73 . 0 0 0 0 0
82 732388D 14 20 1 Kadapa 248 1 8 0 7 1 1 80 26 1 53 100 0 0 1 0 0
83 736797D 15 18 1 Kadapa 248 0 2 0 7 1 1 92 24 1 93 101 0 0 0 0 0
84 735224D 15 24 1 Vellore  5 0 5 0 7 1 1 112 24 1 70 102 0 0 0 0 0
85 735219D 15 22 1 Kadapa 248 0 6 0 5 1 1 112 24 1 60 . 0 0 0 0 0
87 739140D 15 60 1 Kadapa 248 0 5 0 5 1 1 120 22 1 73 99 0 0 0 0 0
88 739133D 15 35 1 Ambur   47 1 15 1 5 2 1 110 20 1 70 99 0 0 0 0 0
89 740478D 5 44 2 Tiruvallu 91 0 6 0 5 1 3 200 18 1 87 . 0 0 0 0 0
90 192293B 1 58 1 Dharmap 136 2 4 0 15 1 1 130 28 1 23 103 0 1 0 0 0
91 739182D 1 35 2 Chitoor  34 0 5 0 10 1 1 92 40 1 70 103 0 0 0 0 0
93 739233D 1 34 1 Kadapa 248 0 4 0 5 1 1 92 36 1 60 100 0 0 1 0 0
94 739134D 1 28 1 Chitoor  34 0 6 0 5 1 1 102 16 1 73 103 0 0 0 0 0
95 739290D 6 30 1 Vellore  5 0 7 0 5 1 3 86 26 3 107 . 0 0 0 0 0
96 739001D 4 17 2 Vellore  5 0 11 1 12 1 1 104 22 1 80 . 0 0 0 0 0
98 735373D 3 20 1 Krishnag 119 2 13 0 5 1 1 120 40 1 87 . 0 0 1 0 0
99 739351D 4 35 1 Vellore  5 0 8 0 10 1 1 80 18 0 93 . 0 0 0 0 0
100 742727D 4 28 1 Vellore  5 0 2 0 5 1 1 88 18 0 93 101 0 0 0 0 1
101 744100D 1 26 2 Krishnag 119 0 3 0 14 1 1 112 24 1 80 . 0 0 0 0 0
102 744307D 1 38 2 Vellore  5 1 3 1 4 2 1 130 40 1 90 99 0 0 0 0 0
103 744246D 1 37 1 Vellore  5 0 2 0 5 1 1 96 26 1 80 104 0 0 1 0 0
105 745413D 1 40 2 Vellore  5 1 7 0 10 1 1 132 44 1 23 102 0 0 1 0 0
106 744172D 15 19 1 Vellore  5 0 4 0 10 1 1 104 24 1 77 99 0 0 1 0 0
107 749618D 13 47 1 Ariur      233 0 4 0 10 1 1 88 . 0 27 100 0 0 1 0 0
109 744179D 1 42 1 Krishnag 119 0 11 0 10 1 1 102 40 1 60 100 0 0 1 0 0
110 750131D 1 33 1 Vellore  5 2 3 1 5 1 1 124 32 1 70 101 0 0 1 0 0
111 750272D 1 45 1 Tiruvaro 244 2 21 1 20 1 1 120 24 1 57 102 0 0 1 0 0
112 745436D 4 19 1 Vellore  5 0 21 0 14 1 1 104 24 1 73 . 0 0 1 0 0
114 753036D 15 50 1 Kadapa 248 2 0 1 5 1 1 112 34 1 90 101 0 0 1 0 0
115 750287D 1 37 1 Chitoor  34 0 8 0 5 1 1 148 45 1 77 . 0 0 0 0 0
116 615538D 1 49 2 Vellore  5 0 4 0 14 1 1 100 22 1 83 . 1 0 0 0 0
117 753023D 1 30 1 Chitoor  34 0 5 0 5 1 1 104 20 1 80 99 0 0 1 0 0
118 753031D 1 45 1 Chitoor  34 0 0 0 15 1 1 100 32 1 73 103 0 0 1 0 0
119 750359D 3 22 1 Chitoor  34 0 14 0 6 1 3 86 26 0 97 98 0 0 1 0 0
120 755440D 6 35 2 Tiruvana 77 0 4 0 15 1 1 112 24 1 83 . 0 0 1 0 0
121 636328D 13 46 1 Vellore  5 1 6 0 10 1 1 92 44 1 80 103 0 0 1 0 0
122 753355D 1 38 2 Vellore  5 2 1 1 7 1 1 120 38 1 60 . 0 0 1 0 0
123 753391D 6 51 2 Vellore  5 0 0 1 7 1 1 130 60 1 63 . 1 1 1 0 0
124 756421D 1 65 1 Gudiyata 29 0 12 0 10 1 1 100 24 1 80 . 1 0 1 0 0
125 757989D 1 72 2 Walajah 25 0 12 0 5 1 1 106 42 1 73 99 0 0 0 0 0
126 759213D 1 25 1 Walajah 25 2 13 1 6 1 1 132 28 1 110 100 0 0 1 0 0
127 765174D 15 28 1 Tiruvana 77 1 18 0 15 1 1 122 28 1 60 99 0 0 1 0 0
128 777169D 15 35 1 Chitoor  34 0 11 1 3 1 1 132 36 1 100 99 0 0 0 0 0
129 777179D 3 16 2 Chitoor  34 2 4 1 3 1 1 150 32 1 20 106 0 0 0 0 0
130 777181D 1 26 1 Vellore  5 1 3 0 5 1 1 110 30 1 70 104 0 0 0 0 0
131 770345D 1 37 2 Tirupattu 91 1 8 0 8 1 1 96 46 1 97 103 0 0 1 0 0
132 774683D 14 45 1 Tiruvana 77 2 8 1 7 1 1 110 48 1 67 . 1 0 0 0 0
134 778200D 1 57 1 Tirupatu 91 1 21 1 3 1 1 160 46 1 . 106 0 0 1 0 0
136 777363D 6 62 1 Ambur   47 1 4 1 5 1 1 124 36 3 63 100 0 0 0 0 0
137 780326D 15 51 1 Chitoor  34 0 5 0 14 1 3 80 24 0 97 99 0 0 1 0 0
138 780145D 1 52 1 Tirupatu 91 0 7 0 6 1 2 140 36 1 93 . 0 0 1 0 0
139 780269D 1 48 1 Chitoor  34 0 8 0 10 1 1 124 28 1 97 101 1 0 1 0 0
140 019439B 6 66 2 Vellore  5 2 4 1 3 1 1 100 30 1 93 . 1 1 0 0 0
141 780029D 3 65 1 Vellore  5 2 11 1 . . . . . 3 . . . . . . .
142 780360D 3 51 2 Vellore  5 1 8 1 5 1 1 . . 3 23 . 0 1 1 0 0
143 780106D 1 60 2 Chitoor  34 0 4 0 5 1 1 124 24 1 127 102 1 0 0 0 0
144 781260D 15 38 1 Chitoor  34 0 9 0 10 1 1 124 26 1 70 105 1 0 0 0 0
145 736718D 1 36 1 Chitoor  34 0 8 1 10 1 1 122 52 1 90 99 0 0 0 0 0
146 780220D 1 45 2 Vellore  5 0 2 0 10 1 1 84 26 1 70 102 0 0 1 0 0
147 780233D 5 71 1 Kadapa 248 0 12 0 10 1 1 110 24 1 110 104 0 0 1 0 0
148 777399D 1 65 2 Kadapa 248 0 7 0 10 1 1 124 28 1 93 100 0 1 0 0 0
149 780244D 3 27 1 Dharmap 136 0 6 0 7 1 1 84 24 1 80 98 0 0 0 0 1
151 785014D 6 68 2 Nellore  236 2 2 1 . . . . . 3 . . . . . . .
152 784704D 3 40 2 Chitoor  34 2 1 1 6 1 1 112 24 1 53 100 0 0 0 0 0
153 782009D 15 50 1 Tiruvana 77 0 23 0 7 1 1 120 38 1 73 101 0 0 1 0 0
157 790004D 15 54 1 Krishnag 119 0 10 0 10 1 1 106 34 1 73 98 1 0 1 0 0
158 788255D 9 38 2 Gudiyata 29 0 3 0 5 1 1 80 22 0 23 . 0 0 0 0 0
159 788256D 1 42 1 Vellore  5 0 4 0 10 1 1 122 46 1 93 102 0 0 1 0 0
160 788090D 15 19 2 Kadapa 248 1 11 0 5 2 1 120 48 1 70 98 0 0 0 0 0
161 789204D 1 55 2 Chitoor  34 2 5 1 7 1 1 116 24 1 73 . 0 0 0 0 0
162 789232D 15 42 1 Tiruvallu 91 2 6 1 12 1 1 112 38 1 27 . 0 0 1 0 0
164 669789D 6 64 1 Tirupatu 91 0 6 0 5 1 1 100 22 1 100 101 1 0 0 0 0
AB AM PRIJA DIA UO MY DE Pal Ict Esc JVPCv ResHep Sp SeizSenGCSVenpH Bic BE LacHb TLC
0 0 0 1 0 0 1 0 1 1 0 1 0 1 0 0 0 1 15 1 . . . . 11 12300
0 0 1 1 0 0 0 1 0 1 0 0 0 2 0 0 1 3 11 1 7.3 16 -10 2 11 5500
0 0 0 1 0 0 1 1 0 1 1 0 0 2 1 1 1 1 11 0 . . . . 14 14100
0 0 0 1 0 1 0 0 0 1 1 0 0 1 1 1 0 0 15 0 7.4 17 -6 3 13 10200
0 0 0 0 0 1 1 0 0 1 0 0 0 0 0 0 0 1 8 1 7.2 7 -18 7 16 26800
0 0 0 0 1 0 1 1 0 0 0 0 0 1 0 0 0 1 15 0 . . . . 13 11200
1 0 1 0 0 1 1 1 0 0 1 0 0 1 0 0 0 0 15 0 . . . . 14 7900
0 0 1 0 0 0 1 1 0 0 0 0 0 0 0 0 0 3 15 0 . . . . 13 10600
0 0 0 0 1 2 0 1 1 0 0 0 0 0 0 0 0 1 13 0 7.4 21 -5 2 4 61200
0 0 1 0 0 0 0 1 0 0 0 0 0 1 0 0 0 1 15 1 7.4 14 -10 3 12 11200
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 15 1 . . . . 12 25000
0 0 1 0 0 1 0 1 1 1 1 0 0 2 0 0 0 1 11 0 7.3 16 -11 3 11 6100
1 1 1 0 0 1 0 1 0 0 1 0 0 0 0 0 0 1 11 0 7.4 19 . . 15 13300
0 0 1 0 0 0 1 1 1 0 0 0 0 3 1 0 0 0 15 0 . . . . 9 14700
1 0 1 0 0 0 0 0 1 0 1 0 0 1 0 0 0 0 15 0 7.4 19 -6 2 11 7900
0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 4 1 . . . . 9 28600
1 0 1 0 0 0 0 1 1 0 0 0 0 0 0 0 0 1 13 0 . . . . 11 36600
1 0 1 0 0 1 1 0 0 0 0 0 0 0 0 0 0 1 8 0 6.8 . . 15 14 17200
0 0 0 0 0 1 0 1 0 0 0 0 0 1 0 0 0 1 11 0 7.5 24 -1 1 13 14100
1 0 1 0 0 0 0 0 1 0 1 0 0 1 0 0 0 0 15 0 . . . . 9 7200
0 0 0 0 0 0 0 0 0 0 1 0 0 1 1 1 0 0 15 1 7.4 21 -5 2 10 8500
1 0 1 0 1 0 0 0 0 0 0 1 0 1 0 0 0 1 15 0 7.4 20 -6 . 13 9400
0 0 0 0 1 0 1 1 0 0 0 0 0 0 0 0 0 0 15 0 . . . . 13 1800
0 0 0 0 1 1 0 0 0 0 0 0 0 1 0 0 0 1 10 0 7.3 18 -9 . 13 30700
0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 15 0 7.4 19 -6 6 13 8100
0 0 0 0 0 0 0 1 0 1 1 0 0 0 1 1 0 1 15 0 7.3 23 -4 3 14 14300
0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 15 0 . . . . 12 7300
1 0 1 0 0 0 0 1 1 0 0 1 0 1 1 1 0 0 15 1 7.5 22 -1 3 8 12800
0 0 0 0 0 0 1 1 0 0 1 0 0 1 0 0 0 0 15 1 . . . . 15 7600
0 0 1 0 0 0 0 0 0 1 0 0 0 1 0 0 0 1 . 1 . . . . 12 11200
0 0 0 0 0 0 0 1 0 1 1 0 0 1 1 0 0 0 15 1 7.4 24 -1 3 14 15300
0 0 0 0 0 0 0 0 0 1 1 0 0 3 1 0 0 0 15 1 7.4 12 -14 4 14 22200
0 0 0 0 1 1 1 1 1 0 0 0 0 1 0 0 0 4 8 1 7.3 8 -19 2 11 8000
0 0 0 0 0 1 0 0 0 0 0 1 0 3 0 0 0 1 9 0 . . . . 13 15400
1 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 15 0 . . . . 12 7000
1 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 15 0 7.5 26 1.7 1 14 6100
0 0 0 0 0 1 0 0 0 0 0 0 0 5 0 0 0 0 15 1 7.3 15 -12 8 13 18200
1 0 1 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 15 0 . . . . 14 1500
0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 1 10 1 . . . . 12 4300
1 0 1 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 15 1 . . . . 13 4300
0 0 1 0 0 1 0 1 0 1 0 0 0 1 0 0 0 0 15 0 7.4 13 -13 11 17 14300
0 0 0 0 1 1 0 1 1 0 0 0 0 0 0 0 0 1 15 1 . . . . 10 8800
0 0 1 1 0 0 0 0 0 1 0 0 0 0 1 1 0 0 15 0 . . . . 12 9600
0 0 0 0 0 0 0 1 1 1 0 0 0 0 1 0 0 0 15 1 . . . . 11 11100
0 0 1 1 0 1 0 0 1 1 0 0 0 3 1 1 1 1 15 1 7.4 18 -5 5 9 8800
. . 0 . . . . . . . . . . . . . . . . 1 . . . . 14 18400
0 0 1 0 1 1 0 0 1 0 0 0 0 1 0 0 1 1 . 1 7.6 20 -2 3 13 6400
0 0 1 1 1 0 0 1 1 1 0 0 0 1 1 0 0 0 15 0 7.4 15 -10 4 5 6800
1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 15 0 . . . . 15 6500
0 0 1 0 0 0 1 0 0 0 0 0 0 1 0 0 1 1 14 1 7.2 16 -11 7 15 6400
0 0 1 0 0 0 1 0 1 1 0 0 0 0 0 0 0 1 7 1 7.4 15 -10 2 13 15800
0 0 0 0 0 0 0 1 0 0 1 0 0 3 1 1 0 0 15 1 7.4 17 -8 2 11 3900
1 0 0 0 0 0 0 1 0 0 0 0 0 1 1 1 0 0 15 0 . . . . 17 2000
0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 15 0 . . . . 14 9200
0 1 1 0 1 0 1 1 0 0 0 0 0 0 0 0 0 0 15 0 . . . . 10 6300
1 0 1 0 1 0 1 0 1 1 0 1 1 1 0 0 0 0 15 1 7.3 17 -9 3 10 14600
1 0 1 0 1 0 1 1 0 0 0 0 0 0 0 0 0 0 15 0 . . . . 16 6900
0 0 0 1 0 0 1 1 0 1 1 0 0 1 1 0 0 0 15 0 . . . . 14 9400
0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 15 0 . . . . 14 4000
1 0 1 0 0 0 1 0 1 1 0 0 0 1 1 1 0 0 15 0 7.3 12 -14 4 15 5800
1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 15 0 . . . . 14 2500
0 0 0 0 0 0 0 0 0 0 1 0 0 1 1 1 0 0 15 0 . . . . 14 9500
1 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 15 0 . . . . 11 11100
0 0 0 0 0 0 0 1 0 0 1 0 0 1 0 0 0 0 15 1 7.4 17 -12 6 12 10800
0 0 0 1 0 0 0 0 1 1 0 0 0 0 1 1 0 0 14 0 7.4 18 -7 2 11 12800
0 0 0 1 0 0 0 1 1 1 0 0 0 0 1 0 0 1 15 0 . . . . 11 9500
0 0 1 0 0 0 0 1 1 1 0 0 0 0 1 1 0 0 15 0 7.3 17 -10 5 11 3200
0 1 1 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 15 0 . . . . 13 7100
0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 15 0 . . . . 8 5100
0 0 0 0 0 0 1 1 1 1 0 0 0 1 1 0 0 0 15 0 7.4 18 -6 1 11 7000
0 0 0 1 0 0 1 1 0 1 0 0 0 0 0 1 0 0 15 0 . . . . 12 7300
0 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 1 4 9 1 7.5 15 -8 7 11 13100
0 0 0 0 1 0 0 0 0 0 0 0 0 4 0 0 0 0 15 0 . . . . 8 16700
1 0 1 0 1 1 0 1 0 0 0 0 0 1 1 0 0 0 15 0 7.4 15 -9 2 14 11200
0 0 0 0 0 1 0 0 1 0 0 1 0 1 0 0 0 0 15 0 . . . . 10 10500
0 0 1 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 15 0 7.3 19 -5 7 14 18500
0 0 0 0 0 0 1 1 0 0 0 0 0 0 1 0 0 0 15 0 . . . . 15 8600
1 0 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 15 0 . . . . 12 10800
1 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 1 1 13 0 7.6 26 3.7 3 11 4700
0 0 1 0 1 1 0 1 0 0 0 0 0 1 0 0 0 0 15 1 7 6 -25 1 15 28300
0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 15 0 . . . . 13 11300
1 0 1 0 0 0 1 1 0 0 0 0 0 0 1 0 0 0 15 0 . . . . 17 6500
0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 15 0 . . . . 11 6600
0 0 0 0 0 0 0 0 0 1 1 0 0 1 1 1 0 0 15 0 7.4 21 -4 3 9 5600
0 0 1 0 0 0 1 1 1 0 1 0 0 1 0 0 0 0 15 0 . . . . 13 11800
0 0 1 0 0 1 0 1 1 0 1 0 0 1 1 0 0 0 15 1 7.4 19 -9 2 10 5800
0 0 1 1 0 0 0 1 1 1 0 0 0 0 1 1 0 0 15 0 . . . . 9 3700
0 0 1 0 0 0 1 1 1 1 0 0 0 0 1 0 0 0 15 0 . . . . 10 7600
0 0 1 0 0 1 1 0 0 1 1 0 0 0 0 0 1 1 14 1 7.3 16 -11 6 18 15800
0 0 1 1 1 1 1 1 0 1 0 0 0 0 0 0 0 4 . 1 7 11 -19 9 11 7400
0 0 1 0 0 2 0 1 0 1 1 0 0 0 0 0 0 1 14 0 7.3 19 -8 1 16 10100
0 0 1 1 1 1 0 1 0 1 0 0 0 0 1 0 0 0 15 0 . . . . 13 13800
0 0 1 1 0 1 1 1 1 1 0 0 0 2 0 1 0 1 . 0 7.3 14 -12 5 10 13800
0 0 0 0 0 0 0 1 1 0 0 0 0 5 0 1 0 0 15 0 7.4 11 -14 9 5 22500
1 0 0 0 1 0 1 1 0 0 0 0 0 0 1 0 0 0 15 0 . . . . 11 11000
0 0 1 1 0 0 1 1 0 1 1 0 0 0 1 0 0 0 15 0 . . . . 13 13000
1 0 1 0 1 0 0 0 1 0 0 0 0 1 1 1 0 0 15 0 7.5 23 -3 2 11 11000
0 0 1 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 15 0 . . . . 10 5100
0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 15 0 . . . . 11 10800
0 0 1 0 0 0 1 1 0 1 0 0 0 0 0 0 0 0 15 0 7.4 22 -6 1 15 4000
0 0 1 0 0 1 1 1 0 0 0 0 0 1 1 1 0 0 15 0 7.1 8 -22 16 14 34600
0 0 1 0 1 1 0 1 0 1 0 0 0 1 0 0 0 0 15 0 7 6 -24 8 14 13800
0 0 1 0 0 0 0 0 1 0 1 0 0 1 0 0 0 0 15 0 7.4 20 -5 2 10 9400
0 0 0 0 0 0 0 0 0 1 1 0 0 1 1 0 0 0 15 1 7.2 14 -14 6 12 7100
0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 1 2 3 1 7.4 26 -2 2 13 17400
0 0 1 1 0 0 1 1 1 1 0 0 0 0 0 0 0 0 11 1 7.3 14 -16 11 16 15500
0 1 1 1 0 1 0 1 1 1 0 0 0 0 1 1 0 1 3 1 7.2 13 -17 0 6 5400
0 0 0 0 0 0 1 1 1 0 0 0 0 1 0 0 0 1 3 1 7.4 16 -13 6 10 34600
0 0 0 0 0 0 0 1 0 1 1 0 0 1 0 0 0 0 15 1 7.4 17 -11 2 11 8200
0 0 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 15 1 7.3 22 -5 1 10 9700
0 0 0 0 0 1 0 1 1 0 0 0 0 0 0 0 0 0 15 1 7.2 12 -19 6 5 13600
0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 1 4 10 1 7.5 23 -3 2 14 16000
0 0 0 0 0 1 0 1 0 1 0 0 0 1 0 0 0 1 13 1 7.3 14 -15 7 12 9500
0 0 1 1 0 0 0 1 1 1 0 0 0 0 1 1 0 0 15 0 . . . . 10 7800
0 0 1 0 0 0 0 1 0 0 1 0 0 1 0 0 0 0 15 0 7.3 ## -18 11 14 2300
0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 13 0 7.4 21 -5 4 13 11600
0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 15 0 7.2 17 -11 1 12 25500
. . . . . . . . . . . . . . . . . . . 0 . . . . 10 8100
0 0 1 0 0 1 0 1 0 0 0 0 0 1 0 0 0 0 15 1 7.2 15 -13 12 14 19800
0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 15 0 7.5 28 -4 1 12 3900
1 0 1 1 0 1 0 1 0 1 0 0 0 0 1 1 0 0 15 0 7.3 17 -11 3 13 7900
0 1 1 0 0 0 0 0 0 0 0 0 0 3 0 0 0 0 15 1 7.5 23 -4 3 12 14700
0 0 1 0 0 1 0 1 1 0 0 0 0 0 0 0 0 0 15 0 . . . . 9 7100
0 0 1 1 0 0 1 1 0 1 0 0 0 1 0 0 0 1 13 0 7.3 14 -16 2 11 15600
0 0 0 0 0 2 0 1 0 0 0 0 0 2 0 0 0 0 15 0 . . . . 13 16700
1 0 1 1 0 0 1 1 0 1 0 0 0 0 1 0 0 0 15 0 . . . . 18 22600
. . . . . . . . . . . . . . . . . . . 1 . . . . 13 37700
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 15 1 6.8 . . 20 12 42700
0 0 1 1 0 1 0 1 0 1 0 0 0 0 0 0 0 1 13 0 7.3 6 -22 7 6 9700
0 0 1 1 0 1 0 0 0 1 0 0 0 1 0 0 0 0 15 0 7.4 19 -9 18 9 7100
0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 15 0 . . . . 9 9200
0 0 1 1 0 1 0 0 0 1 0 0 0 0 1 0 0 0 15 0 7.4 17 -12 3 16 14100
0 0 0 1 0 1 0 1 1 1 0 0 0 0 1 1 0 0 15 1 7.4 19 -9 3 8 6800
1 0 1 1 0 1 0 0 1 1 1 0 0 1 1 0 0 4 6 1 7.2 14 -0 2 8 12300
0 0 1 0 0 1 0 0 0 1 0 0 0 1 0 0 0 0 15 1 7.2 11 -20 9 13 18500
1 0 1 0 0 0 1 1 0 0 0 0 0 0 0 0 0 1 9 0 . . . . 13 8000
NeuPlat PT CreaNa K BicaTB DB TP Alb AST ALT MPPI MPMPWid Wid Wid Wid Sa Dab
82 64000 11 4.9 127 4.8 12 8.2 6.3 6.2 2.9 100 111 0 . . . 0 40 1280 40 1 0
74 70000 12 6.6 131 3.8 15 7.7 6.5 6.1 2.8 71 51 0 . 0 0 0 40 40 0 1 0
65 51000 11 1.1 122 3.9 20 12 9.2 6.7 2.7 172 188 0 . 0 0 0 20 20 40 1 0
72 30000 13 4.9 . . . 7.5 5.7 6.2 2.6 127 65 0 . . . 20 0 0 0 1 0
76 60000 16 4.6 137 4.7 10 3.7 2.8 6.9 2.8 100 111 0 . 0 . 0 40 0 0 1 1
85 88000 9 0.9 130 3.2 24 0.4 0.2 6.5 3 96 27 0 . 0 0 0 0 20 0 1 0
75 90000 . 1.4 129 3.8 20 0.6 0.3 6.2 3.5 96 154 0 . 0 0 0 0 0 0 1 0
77 60000 . 1.1 135 3.8 20 0.5 0.3 5.1 1.8 84 75 0 . 0 . . . . . 1 0
58 296000 17 4.4 131 5.9 60 1.5 1.2 4.2 2.4 8500 2600 0 . 0 0 0 20 0 0 0 1
85 60000 12 1.7 . 4.1 14 0.5 0.2 5.3 1.9 224 109 0 . 0 . . . . . 1 .
85 559000 16 2.3 137 5 16 0.4 0.2 7.6 3.4 48 38 0 . 0 . 0 0 0 0 0 0
72 58000 . 4.4 132 5.3 13 4 2.1 5.5 2.5 72 24 0 . . . . . . . 1 .
81 298000 11 1.1 133 4.4 22 0.4 0.2 8.8 4.4 34 27 0 . 0 . . . . . 1 .
83 90000 . 0.8 134 3.5 22 0.6 0.2 8.3 3.8 81 64 0 . . . . . . . 1 .
82 107000 13 0.7 139 3.5 19 0.7 0.2 5.9 2.9 95 53 0 . . . . . . . 1 .
79 35000 12 1.4 134 3.1 17 0.5 0.2 6.9 2.8 134 128 0 . 0 0 . . . . 0 .
87 209000 16 2.4 126 4.4 11 0.5 0.2 5.2 2 142 29 0 . 0 . 0 20 0 0 1 1
71 249000 25 2 139 4.6 7 3 2 7.4 4.7 341 203 0 . 0 . . . . . 0 0
66 33000 . 1.8 132 3 18 0.6 0.3 7.8 3.1 149 77 0 . 0 . . . . . 1 0
93 16000 . 0.9 . . . 0.4 0.2 6.1 2.9 88 62 0 . 0 0 0 0 0 0 1 0
73 62000 15 1 135 3.9 16 1.4 0.7 5.3 2.4 236 101 0 . . . . . . . 1 .
72 12000 13 1.1 129 4 15 0.7 0.2 7.1 2.8 366 179 0 . 0 0 . . . . 1 1
44 75000 . 1.4 125 4 21 0.5 0.3 5.9 3.3 224 61 0 . 0 0 80 1280 20 0 . .
70 249000 20 5.6 154 2.9 17 0.8 0.2 6.4 3.6 84 37 0 . . . . . . . 0 .
75 28000 12 0.9 136 3.2 17 2.3 2 5.1 2.7 215 117 0 . 0 0 . . . . 1 1
52 6000 13 1 123 6.2 19 6.8 5.7 7.1 2.8 133 277 0 . 0 0 . . . . 1 .
72 180000 . 1 133 3.9 18 0.4 0.2 6.6 3.2 105 66 0 . . . . . . . 1 .
86 7700 13 0.4 126 2.8 . 2.2 1.9 5.1 2.2 2.9 59 0 . 0 . . . . . 0 1
76 173000 15 1.1 134 3.6 23 2 0.2 7 3.3 140 97 0 . 0 . . . . . 1 .
82 35000 12 1.5 138 3.9 13 3.1 2.5 6 2.3 220 131 0 . 0 . . . . . 1 1
85 105000 . 1.5 136 3.7 20 1.3 0.2 7.4 3.5 82 63 0 . 0 . . . . . 1 .
84 29000 11 2.8 140 4.4 9 5.6 2.4 6.8 2.4 299 89 0 . . . . . . . 1 1
68 45000 14 5.1 143 3.7 10 0.7 0.1 4.8 2 454 167 0 . 0 0 40 320 0 0 0 0
94 102000 . 6.9 135 4.5 10 3 2.2 4.9 2.2 115 71 0 . 0 . . . . . 1 1
70 110000 . 0.9 132 3.5 27 0.8 0.3 7.6 3.8 58 35 0 . 0 . 0 0 0 0 1 .
60 90000 . 0.9 135 4.3 22 0.4 0.2 7.3 3.8 22 10 0 . 0 0 . . . . 0 0
87 14000 14 1.1 134 4.1 13 0.5 0.2 4.5 1.6 141 41 . . . . . . . . 1 1
14 63000 11 0.9 140 3.6 28 0.5 0.2 7.3 4.6 277 123 0 . 0 . 0 0 0 0 0 1
50 45000 13 1.9 139 3.9 13 4.9 2.7 7.2 3.3 90 27 0 . 0 0 . . . . 1 .
88 36000 11 1.5 129 3.6 23 0.7 0.2 5.9 3.2 201 49 0 . 0 . 160 640 0 0 0 .
44 114000 18 4.3 134 3 14 4.3 1.6 6.3 3.2 217 113 0 . 0 0 . . . . 0 0
79 66000 29 2.6 138 4.2 13 1.8 1.4 5.5 3 1231 435 0 . . . . . . . 0 0
53 75000 14 9.9 133 4.9 14 4.6 3 6.3 2.8 40 44 1 . 1 1 . . . . 1 .
69 136000 12 1 126 2.9 18 2.2 1.6 6.8 3 362 110 0 . 0 . . . . . 1 1
71 18000 14 1.3 138 3.7 17 6.5 5.4 5.1 2.5 424 184 0 . . . . . . . 0 1
84 120000 20 2.4 131 3.2 17 3.3 0.3 6.9 3.6 246 187 0 . 0 . . . . . 0 .
72 125000 26 1 121 2.7 23 0.5 0.1 6.7 4.1 87 46 0 . . . 0 0 0 0 0 .
54 75000 32 2.3 141 4.1 11 7.2 5.7 5.3 3.2 348 75 0 . 0 0 0 0 0 0 0 0
54 174000 . 1 137 3.8 21 0.7 0.2 7.8 4.5 481 391 0 . 0 0 160 160 0 0 . .
77 255000 13 2.4 129 4.2 13 0.5 0.2 8.9 3.8 119 39 0 . 0 . . . . . . 0
69 35000 11 6.9 137 5.2 14 4 3.1 7.3 2.9 135 39 0 . 0 0 . . . . 1 0
76 48000 13 1.1 132 2.9 21 1.5 1.2 6.9 3.3 327 169 0 . 0 . . . . . 1 .
28 10000 10 1.4 132 4.7 22 0.7 0.2 7.2 4 73 18 0 . . . . . . . 0 0
14 43000 11 1.3 140 4.3 18 1.6 0.6 7.7 3.7 80 18 0 . . . . . . . 0 1
58 6000 12 0.7 137 4.6 21 0.7 0.2 5.6 2.5 44 12 1 . 1 . . . . . . .
55 52000 20 2.7 143 4.3 15 3.1 2.7 5.7 3 72 25 0 . . . 0 0 0 0 0 0
69 167000 . 1.4 127 3.7 20 0.5 0.2 6.8 3.7 66 75 0 . . . . . . . . .
77 97000 . 1 124 3.6 19 3.6 3 7.2 3.6 103 107 0 . 0 0 0 0 0 0 1 .
49 59000 . . . . . 0.5 0.2 6.1 3.1 24 12 1 . 1 1 0 0 0 0 . .
91 15000 11 3 127 5.6 12 1.1 0.2 6.7 2.2 71 66 1 . 1 . 0 80 0 0 . .
33 61000 . 1 133 4.1 19 0.5 0.3 7.7 4.1 474 209 0 . . . . . . . 0 1
74 22000 . 2.1 136 3.7 16 3.8 2.7 7 3.6 168 159 0 . . . . . . . 1 .
95 200000 . 1.3 132 4.7 20 1 0.1 8.2 3.5 41 42 0 . 0 0 0 40 20 0 1 1
77 24000 17 1.3 134 4.2 14 0.7 0.2 6.6 2.1 122 147 0 . 0 0 . . . . 1 1
79 24000 12 7.5 129 4.6 17 29 27 6.3 3.2 140 83 1 . 1 . . . . . . 0
64 19000 14 3.4 128 4 19 23 21 5.9 2.4 54 13 1 1 1 1 . . . . . .
58 21000 13 1.5 131 5.2 18 1.3 0.4 5 2.3 78 30 1 2 1 . . . . . . .
60 31000 . 1.1 . . . 0.5 0.2 6 3.3 83 59 1 . 1 1 . . . . . .
98 9000 . 1.3 134 3.3 21 16 0.2 5.2 2.4 68 24 1 3 1 1 . . . . . .
70 7000 . 1.2 137 4.7 22 2.9 1.6 5.7 2.8 108 58 1 1 1 1 . . . . . .
69 16000 . 0.7 134 3.2 22 18 15 6.1 2.9 39 13 1 . . . . . . . . .
79 8000 . 1 138 5.1 10 2.3 1.3 6 3.3 42 71 1 2 1 1 . . . . 0 .
65 200000 . 1.3 127 4.9 10 . . . . . . 0 . . . 0 0 0 0 0 0
86 102000 . 5.3 120 4.9 13 2 0.9 7.7 2.8 209 102 0 . 0 . . . . . 1 .
55 157000 . 0.9 126 3.5 22 0.4 0.2 6.3 1.9 71 37 0 . 0 0 20 0 20 0 1 1
71 50000 16 0.7 132 5.6 20 0.8 0.2 8.6 3.8 27 37 0 . . . . . . . 1 1
81 49000 . 1.5 130 4.1 23 0.5 0.2 7.7 3.7 139 252 0 . . . . . . . 1 .
79 260000 15 12 132 3 11 0.2 0.1 6.9 3.7 24 7 . . . . . . . . 0 0
81 81000 . 0.9 139 3.9 20 0.4 0.2 7.1 3.4 85 28 . . . . . . . . . .
87 157000 16 15 133 3 5 0.4 0.3 5.9 3.3 59 7 0 . . . 0 0 0 0 0 1
54 193000 13 1.1 135 4.8 28 0.2 0.1 7.6 3.3 70 . 0 . 0 . 0 20 320 40 . 1
70 144000 . 1 133 3.5 21 0.6 0.4 7.9 4.3 132 129 0 . 0 0 0 0 0 0 . .
59 160000 . 0.8 131 3.6 25 0.4 0.4 6.7 2.8 37 28 0 . 0 . 20 0 0 0 1 .
73 27000 13 0.9 134 3.7 18 1.2 0.5 6.1 2.9 148 104 0 . 0 0 . . . . 1 0
94 152000 . 1.2 125 3.4 . 1.2 0 7.4 3.4 75 71 0 . . . . . . . 1 .
93 17000 15 1.1 139 3.8 16 0.4 0.2 5 2.1 74 27 0 . . . . . . . 1 .
45 15000 . 1.3 137 4 17 1.1 0.9 5.6 2.3 75 39 1 2 . . . . . . . .
90 200000 . 1 131 3.2 . 3.2 1 5.6 2.3 36 20 1 . 1 1 . . . . 0 .
72 30000 12 2.9 130 4.2 11 5.7 3.9 4.7 1.7 221 87 0 . 0 . . . . . 1 .
87 66000 16 6.9 133 4.7 11 1.9 0.2 6.9 3 208 114 0 . 0 0 . . . . 1 1
90 13000 14 7.6 128 4.1 7 5.8 5.1 7.9 2.2 205 30 0 . 0 . . . . . 1 0
93 164000 14 6 133 8.5 7 25 20 5.3 2.4 124 122 0 . 0 0 320 #### 2560 640 0 0
84 27000 13 4.9 118 5.3 14 31 30 4.9 2.4 194 44 1 1 1 . . . . . . .
82 151000 18 2.2 132 4.9 12 0.9 0.2 4.5 1.6 237 94 0 . 0 . 0 0 0 0 1 .
89 119000 . 4.7 129 3.8 17 0.8 0.2 6.6 2.9 60 51 0 . . . . . . . 1 .
47 91000 . 1.8 131 3.9 18 4.3 3.6 7.4 3 98 102 0 . 0 . . . . . . .
81 9000 . 1.3 132 4.2 20 0.1 0 6.2 2.2 218 34 0 . 0 0 0 0 0 0 1 .
39 36000 13 0.9 136 3.8 25 0.4 0.2 6.1 3.4 183 137 0 . 0 0 . . . . 0 1
76 19000 . 1.2 . . . 0.5 0.1 7.1 3.3 21 11 0 . 0 0 40 0 0 0 0 .
77 73000 . 1.7 132 3.9 22 2.4 0.4 6.8 3.8 40 27 1 . 1 0 . . . . . .
60 600000 18 2.8 130 4.4 10 0.4 0.2 5.8 2.2 235 29 0 . 0 . . . . . 1 0
85 61000 15 7.2 134 5.3 6 5.3 3.1 6.2 2.7 141 54 0 . 0 . . . . . 0 0
90 77000 . 5.6 130 4.3 16 0.5 0.1 6.2 2.4 123 53 0 . . . 0 10 80 0 1 0
80 22000 . 3.1 131 3.7 11 2.6 0.3 7.6 3 185 43 0 . 0 . . . . . 1 .
92 146000 11 4.7 129 4.4 14 0.5 0.2 6.4 3.3 49 11 0 . 0 . . . . . 1 .
77 91000 14 0.7 130 4.2 14 2.3 0.8 5.9 1.9 140 53 1 . 1 1 . . . . . .
70 15000 17 8.6 135 4.1 14 26 18 6.1 2 95 26 1 . 1 1 . . . . . .
91 60000 17 2 132 3.7 12 1.1 0.2 4 1.8 159 57 0 . . . . . . . 0 0
77 64000 13 1.2 132 4.3 2.8 2.1 2.1 6.4 2.6 132 97 0 . 0 . 0 0 0 0 1 .
79 94000 14 2.5 138 3.8 14 0.5 0.2 6.1 2.5 86 39 0 . 0 . . . . . 1 .
34 18000 14 4 125 4.6 8 1.8 1.3 5 2.4 355 177 1 . 1 1 . . . . 0 .
82 115000 13 1.9 133 2.8 21 0.7 0.3 6 2 251 75 0 . 0 . . . . . 1 0
84 60000 14 3 125 3.8 9 2.1 0.2 5.1 2.2 60 14 0 . 0 . . . . . 0 0
61 8000 11 1.3 136 4.9 17 28 28 5.1 2.7 51 22 1 . 1 1 . . . . . 1
53 237000 16 1.4 136 3.8 14 0.6 0.2 7.7 4 103 19 0 . 0 . . . . . 0 .
62 117000 . 1.5 121 4.2 18 0.4 0.2 8.3 3.6 198 180 . . . . . . . . 1 1
78 44800 12 1.6 112 4.5 17 0.4 0.2 5.3 3.7 15 11 . . . . . . . . 0 0
83 91000 13 1.1 118 3.3 . 1.2 0.7 5.3 3.3 298 90 0 . 0 . . . . . 0 1
90 21000 33 3.6 133 4.6 22 1.5 0.6 7.1 2.3 20 36 0 . 0 0 . . . . 0 1
74 41000 11 0.9 124 3.2 27 1.1 0.9 7.4 3 140 120 0 . 0 . . . . . 0 0
65 15000 . 2.9 135 4.5 16 7.4 3.5 6 2.7 134 61 1 . 1 1 0 20 0 0 . .
58 9000 13 1.1 138 3.6 19 0.4 0.2 7.4 3.3 120 74 0 . 0 . . . . . 1 1
89 49000 . 1 124 3.4 20 0.5 0.2 7.7 2.8 109 33 0 . 0 . . . . . 1 .
88 163000 17 6.3 127 5.7 10 6.2 3.2 6.6 2.4 68 24 0 . 0 0 0 40 0 0 0 0
94 14000 12 1.4 137 5.1 13 0.8 0.4 5.4 1.4 101 20 0 . . . . . . . 1 0
63 31000 15 1.1 138 4.5 16 7 4 7.8 4.1 2008 1039 0 . 0 0 . . . . 0 0
95 2E+06 29 1.5 125 5.2 13 0.5 0.2 5.7 2.4 479 116 0 . 0 . . . . . 0 0
55 36000 14 2.1 140 4.8 10 2.1 0.8 6.3 2.9 1583 592 0 . . . . . . . 0 1
57 69000 12 4.7 133 5.8 10 18 13 6 2.4 127 31 1 . 1 1 . . . . . .
67 11000 9.5 1.2 128 5.5 22 10 9.5 5.6 2 39 20 1 . 1 1 . . . . . .
58 16000 11 0.8 138 3.4 18 0.5 0.1 5.3 2.8 61 40 0 . 0 . . . . . 0 0
94 61000 11 2.2 128 3.8 12 6.5 5.5 6.5 2.6 298 111 0 . 0 0 . . . . 1 0
91 13000 15 1 137 3.8 14 13 13 5.3 2.1 44 19 1 . 1 1 . . . . . .
72 90000 28 2.8 146 5 11 8.9 7.4 5.2 1.9 225 73 0 . 0 . . . . . 1 .
64 20000 16 4.9 121 5.7 7 18 12 7.2 3.5 113 61 1 1 1 1 . . . . . .
77 112000 . 1.8 140 4.4 18 1.1 3 5.9 2.7 23 28 0 . 0 0 . . . . 0 .
Aa LepSL UGUB UBUSpg Up UNUleURBUW Ca GrCBCUC Dur UCr UNa UK UCl UPUDBUDCr BucrDCyDNa
0 0 . 0 1 3 1.02 5 0 0 0 2 0 0 0 . 0 . . . . . . 4.9 . 5.1 .
0 0 . 1 1 3 1.01 6 0 0 2 6 0 0 0 0 0 48 88 18 58 1.8 88 4.8 18 3 132
0 . . . . . . . . . 4 0 0 0 0 0 0 83 93 29 77 0.3 46 1 46 2.4 124
0 0 . 1 2 3 1.03 5 0 0 99 0 0 0 0 . 0 86 52 31 39 0.9 256 6.8 37 13 133
0 0 . 0 1 3 1.02 5 0 0 99 6 2 1 0 0 0 152 16 44 21 0.3 . . . . .
0 0 . . . . . . . . 6 8 5 1 0 . 0 . . . . . 6 0.7 8.6 1.1 137
0 0 . . . . . . . . 6 8 5 1 0 0 . 63 50 9 44 0.5 19 1.2 16 1.5 137
0 0 0 . . . . . . . 10 12 5 1 0 0 . 49 75 19 72 0.6 62 1.2 52 2.1 134
1 0 0 0 1 3 1.01 6 0 0 20 0 0 0 0 . 0 40 95 37 94 4.5 . 6.7 . 5.8 138
. . . . . . . . . . 4 35 5 1 0 0 0 80 3 39 18 1.3 97 1.6 61 2.5 132
0 0 . . . . . . . . 40 6 . 0 0 . . 80 85 28 82 0.1 . 1.7 . 2.8 130
. . . . . . . . . . . . . 0 0 . . 24 104 12 105 0.6 147 2.2 67 3.5 147
. . . . . . . . . . . . . 0 0 . . 60 153 21 159 0.4 43 1 43 1 136
. 0 0 . . . . . . . 12 6 0 0 0 . 0 57 196 21 166 0.6 20 0.6 33 1.4 137
. . 0 . . . . . . . 6 5 5 1 0 0 . 63 38 34 84 0.6 45 0.9 50 1.9 141
. 0 . . . . . . . . 12 3 2 1 0 . . 64 106 40 74 0.8 . . . . .
0 . . 0 0 0 1.02 5 0 0 10 6 5 1 0 0 0 74 32 45 40 2.1 137 3 46 4.1 128
0 0 . . . . . . . . 12 2 0 0 0 . 0 . . . . . 47 2.6 18 3.6 124
0 0 0 . . . . . . . 6 2 0 0 0 . . 19 102 13 118 1.1 38 1.1 35 1.8 127
0 . . . . . . . . . 2 8 1 1 0 . . 20 142 13 143 0.8 18 0.9 20 2.2 120
. . . . . . . . . . 3 5 5 1 0 . . 47 34 17 46 0.9 32 0.9 36 1.3 178
0 . 0 . . . . . . . 6 4 5 1 0 . . 20 76 8 76 0.1 . 0.9 . 1.4 138
. . . . . . . . . . 0 2 0 0 1 . . 178 21 30 27 1.3 54 1.4 39 1.8 131
. 0 0 0 0 2 1.01 6 0 0 4 2 0 0 0 . 0 104 97 23 77 0.5 75 4.6 16 5.9 136
1 0 0 . . . . . . . 2 5 5 1 0 . . 39 99 13 94 5.7 116 2.4 48 2.7 140
. . 0 . . . . . . . . . . 0 0 . 0 33 138 21 147 0.2 30 0.7 43 2.1 121
. . . . . . . . . . 4 4 5 1 0 . . . . . . . 28 0.9 31 1.3 134
0 0 . 0 0 3 1.01 7 0 0 25 4 1 1 0 0 0 95 3 26 67 5.3 31 0.6 52 1.5 141
. . . . . . . . . . . . . 0 0 . 0 113 138 11 160 0.9 29 1.1 26 1.1 136
0 0 0 0 0 1 1.01 6 0 0 0 4 5 1 0 . 0 . . . . . 202 4.1 49 7 149
. . . . . . . . . . 8 15 5 1 0 0 . 149 117 35 157 0.8 42 0.9 47 1.5 144
1 0 0 . . . . . . . . . . 0 0 . . 38 110 33 124 0.6 80 1.1 73 2 140
0 0 . . . . . . . . 99 15 2 1 1 0 0 115 30 30 26 3.2 . . . . .
0 0 0 . . . . . . . 8 4 2 1 0 . . 38 107 18 94 1.2 230 6.4 36 6.7 108
. . . 0 1 1 1.01 7 0 0 6 2 1 1 0 0 . 49 190 16 213 0 9 0.8 11 1 136
0 0 0 0 0 0 1.03 6 1 0 3 4 2 1 0 . . 101 22 23 38 0.2 29 0.8 36 1.4 122
1 0 0 . . . . . . . . . . 0 0 0 . 95 60 23 68 0.1 . . . . .
1 0 . 0 0 0 1.01 6 0 0 . . . 0 0 . . 96 69 42 56 0.7 97 2.2 43 3 130
. 0 . . . . . . . . 2 6 5 1 0 0 . 90 8 42 16 0.7 124 1.8 69 2.5 120
. . . . . . . . . . 2 2 0 0 1 . 0 101 88 18 79 0.6 43 1.7 25 1.6 128
0 0 0 0 0 3 1.01 6 1 0 12 4 0 0 0 0 0 80 42 48 58 0.6 . 6.7 . . 134
0 0 0 . . . . . . . 6 10 5 1 0 . 0 32 143 12 110 8.4 . 4.2 . 3 188
. 0 . 0 1 2 1.02 6 0 0 12 2 0 0 0 . 0 38 73 8 62 0.7 204 11 18 3.5 127
0 0 0 0 1 1 1.01 6 0 0 5 10 0 0 0 0 0 55 161 28 190 0.8 24 0.7 34 1.7 136
0 0 . 0 0 1 1.01 7 0 0 99 99 0 0 0 1 0 28 2 13 17 0.3 85 1.3 67 2.4 145
. 0 0 2 0 3 1.01 6 0 0 12 4 5 1 0 0 . 8 97 9 74 13 111 3.6 31 2.3 144
. 0 0 0 0 0 1.02 7 0 0 12 4 0 0 0 0 0 24 78 8 54 4.1 42 2.2 19 1.4 130
0 0 . . . . . . . . . . . 0 0 . 0 13 106 8 81 1.6 . 1.7 . 1.3 117
. . 0 . . . . . . . 4 8 0 0 1 0 . 185 97 28 94 0 13 1 13 1 113
0 . . . . . . . . . 5 6 5 1 0 . . 22 90 13 85 1.7 65 2.3 28 1.9 128
0 0 0 . . . . . . . 2 4 0 0 0 0 . 46 50 57 48 2.1 291 7 42 6.2 148
. . . 0 0 1 1.01 6 0 0 2 0 0 0 0 0 0 70 61 34 59 1.2 . 1.2 . 1.7 134
1 . 0 . . . . . . . 0 5 0 0 0 . 0 35 56 3 42 0 16 1.2 13 1.3 135
0 . 0 0 0 2 1.01 6 0 0 20 5 5 1 0 . 0 37 97 15 94 0.1 25 1.6 16 1.6 142
. . . . . . . . . . 2 2 0 0 . . 0 63 178 28 217 0 13 0.7 19 0.9 136
0 0 0 0 1 2 1.02 6 0 0 6 0 0 0 0 . . 43 114 31 113 0.4 . . . . .
. . 0 . . . . . . . 0 2 0 0 1 . . 173 22 39 30 0.5 37 1.5 25 1.8 128
. . . 0 1 1 1.01 6 0 0 2 2 0 0 0 . 0 77 33 14 48 0.6 20 0.8 25 1.4 132
. . . 0 0 1 1.01 6 3 0 . . . 0 0 . . 39 75 6 70 0.1 16 1.1 15 2 138
. . . . . . . . . . 5 5 5 1 0 . . 39 140 12 159 0.5 69 1.3 53 1.6 133
0 . 0 . . . . . . . . . . 0 . . 0 162 30 24 38 0.1 26 0.9 29 1.1 139
. . . 0 1 2 1.01 6 0 0 10 6 0 0 0 . . 62 73 11 60 0.5 . 2 . 1.8 138
0 0 0 . . . . . . . 4 4 0 0 1 . . 39 59 8 52 0.1 22 1.1 20 1.6 131
0 . . 0 0 2 1.01 6 1 1 6 4 5 1 0 . 0 105 11 36 30 0.8 84 1.1 76 2.7 135
1 . . . . . . . . . . . . 0 0 . 0 43 99 12 73 1.6 321 8.7 37 5.5 129
. . . 0 2 3 1.01 6 0 0 99 6 0 0 0 . . 54 74 12 66 0.7 . 1.8 . 1.5 .
. . . . . . . . . . . . . 0 0 . 0 79 135 40 159 0 . 0.8 . 1.1 .
. . . 0 1 1 1.01 9 0 0 6 0 0 0 0 . . 103 129 18 118 0.5 . 1.4 . 1.2 .
. . . . . . . . . . 0 1 0 0 0 . 0 24 182 8 203 0.2 21 1 21 1 134
. . . . . . . . . . 4 20 5 1 0 . . 34 185 23 206 1.1 . 1 . 0.9 .
. . . . . . . . . . 8 4 5 1 0 . . 57 103 19 141 0.4 . 0.7 . 1.3 .
. 0 . . . . . . . . 6 2 0 0 0 . 0 27 111 17 104 1.2 62 0.9 69 1.2 137
0 0 0 2 0 1 1.01 6 0 0 20 2 0 0 0 1 . 59 139 6 97 1.3 . . . . 136
. . . 0 1 2 1.01 7 0 0 12 0 2 1 0 . . 177 34 37 21 0.3 . 3.1 . 4.1 .
0 0 0 . . . . . . . 0 4 0 0 0 . . 63 100 12 52 0.3 23 0.8 29 2.1 125
1 1 . . . . . . . . 6 4 0 0 0 . . 125 29 24 41 0.5 . 1 . 2.2 .
. . . . . . . . . . 3 8 0 0 0 1 . 163 152 24 151 0 21 1 21 1.4 137
0 0 0 0 0 3 1.01 6 0 0 25 3 0 0 0 1 0 37 73 8 71 1.4 242 8.9 27 3.4 126
. . . . . . . . . . . . . 0 1 . 0 . . . . . 34 0.8 43 1 139
1 0 . 0 0 3 1.01 6 0 0 6 3 2 1 0 . 0 28 127 6 118 1.1 358 17 21 5.6 138
0 0 . . . . . . . . 0 0 0 0 0 . 0 46 106 18 76 0 40 1.1 36 1.9 133
. . . . . . . . . . 6 12 0 0 1 1 . 37 47 9 45 0.4 18 1.4 13 1.3 129
. . . . . . . . . . 40 4 0 0 0 . . 91 243 8 223 0.1 14 0.9 16 1.4 126
0 0 0 0 2 2 1.02 6 0 0 10 2 1 1 0 . . 171 22 ## 157 1 54 0.8 68 1.5 134
. . . . . . . . . . 2 0 0 0 0 . . 151 55 48 80 1 25 1 25 1.6 127
. 0 . . . . . . . . 35 35 0 0 0 1 . 24 120 10 127 0.9 23 0.8 29 1.5 134
. . . . . . . . . . 2 6 0 0 0 . . 95 171 15 169 0.4 34 1.4 24 1.5 125
. 0 . 0 1 1 1.02 6 0 0 3 0 1 1 0 . . 106 88 81 101 0.3 32 0.7 46 1 127
. 0 . 0 1 3 1.01 6 0 0 50 10 1 1 0 . . 58 199 24 213 2.2 . 1.2 . 2 144
1 0 0 . . . . . . . . . . 0 0 0 0 137 61 47 23 1.7 185 7.9 23 4.6 136
0 0 . . . . . . . . 12 0 0 0 0 0 . 123 68 24 28 0.7 . 6.6 . 7.4 132
0 0 . 0 2 2 1.01 6 0 0 10 6 0 0 1 . 0 46 60 15 54 1 102 4 26 3.9 121
. . . . . . . . . . . . . 0 0 . 0 52 23 37 28 0.8 166 2.9 57 0.9 123
. . . . . . . . . . 3 3 0 0 0 . 0 72 86 17 58 0.6 85 1.6 53 2.6 150
. 0 . 1 1 2 1.01 6 0 0 12 8 0 0 0 0 . 82 38 11 26 0.5 91 2.1 43 3.3 131
. . . 0 3 1 1.03 6 0 0 3 0 0 0 0 . . 165 151 28 200 0.6 39 1.4 28 2 136
. . . 0 0 2 1.01 6 0 0 12 2 0 0 0 . . 42 166 39 196 0.4 53 0.9 59 1.6 141
1 0 0 . . . . . . . 0 0 0 0 0 . 0 63 129 20 161 0.1 23 0.9 26 0.8 138
. 0 0 0 0 2 1.01 6 0 0 12 0 0 0 0 . 0 53 45 11 49 0.2 27 1.2 23 1.4 136
. . . . . . . . . . 20 99 0 0 0 0 . 63 143 15 148 0.3 28 1.2 23 1.2 137
0 0 0 . . . . . . . 4 10 0 0 0 0 0 82 18 27 19 1.2 144 4.7 31 4.7 145
0 0 0 0 1 2 1.01 6 0 0 10 4 0 0 0 . 0 41 111 24 93 2 156 8.1 19 16 132
0 . 0 0 0 0 1.01 6 0 0 12 12 0 0 0 . . 52 102 19 102 0.7 68 2.4 28 2.2 140
. . . . . . . . . . . . . 0 0 . . 76 16 35 14 1.4 114 1.6 71 3.5 152
. . . 0 0 3 1.01 6 0 0 20 4 0 0 0 . 0 42 79 24 87 1.9 104 6 17 5.3 123
. . . 0 0 2 1.01 6 0 0 8 6 0 0 0 . 0 29 79 26 65 2.8 122 3.2 38 1.2 132
. . . . . . . . . . . . . 0 0 . . 38 116 12 99 4.2 . 10 . 4 142
1 0 0 . . . 1.01 7 . . 35 20 1 1 0 . . 5 46 4 40 1.2 . . . . .
. . . 0 0 2 1.01 6 0 0 8 8 2 1 0 . . 36 193 26 217 2.2 30 0.8 38 1.7 133
. . . . . . . . . . 15 50 1 1 0 . . 43 117 14 53 0.2 19 0.6 32 1.5 136
. 0 . 0 0 3 1.01 6 0 0 10 2 0 0 0 . 0 30 89 27 71 3.4 198 6.6 30 6.2 136
0 0 0 0 0 3 1.01 6 0 0 2 4 0 0 0 1 0 . . . . . 67 2.2 30 3.3 130
0 0 . . . . . . . . 28 8 2 1 0 . 0 31 97 32 98 3.3 . 5.3 . 5.4 140
0 . 0 . . . . . . . 2 3 2 1 . . 0 80 37 32 36 0.9 79 1.3 61 2.3 130
. . . 0 0 0 1.02 6 0 0 0 0 0 0 0 . 0 28 107 9 119 0.6 15 0.8 19 1.1 139
0 0 0 1 0 2 1.02 6 0 2 . . . 0 0 . . 68 177 28 196 1 34 1.1 31 1.1 126
0 0 . . . . . . . . 0 0 1 1 0 . 0 69 41 40 37 2.2 46 3 15 2.4 142
0 0 0 0 0 3 1.01 6 0 0 20 3 0 0 0 . 0 . . . . . . 1.4 . . 148
0 0 0 0 0 3 1.01 6 0 0 99 0 0 0 0 . 0 22 130 16 135 5.2 101 4.4 23 4.9 140
0 0 0 . . . . . . . 12 2 2 1 0 . . 17 40 9 43 5.7 24 0.9 27 1.7 111
. . . . . . . . . . 30 4 0 0 0 . . . . . . . 68 1.5 45 1.6 123
1 . . . . . . . . . 3 10 5 1 0 . . 102 8 24 17 4 54 0.8 68 1.4 131
. . . . . . . . . . . . . 0 0 . . 41 179 20 222 1.2 18 0.8 23 1.9 112
0 1 0 . . . . . . . 6 4 0 0 0 0 0 34 71 25 65 1 368 6.1 60 4.2 119
0 0 0 0 0 2 1.01 6 0 0 12 0 0 0 0 . . 18 78 14 78 0.5 37 0.8 46 1.7 115
1 0 0 . . . . . . . 2 2 0 0 0 . 0 71 104 17 125 0.4 96 1 96 1.3 118
0 0 0 . . . . . . . 6 2 0 0 0 . . . . . . . 70 1.1 61 1.5 137
1 0 0 . . . . . . . 8 12 0 0 0 . 0 . . . . . 45 2.5 18 2.1 147
. . . 1 0 2 1.01 7 0 0 6 4 0 0 0 . 0 59 69 22 38 2.5 189 5.3 36 6.2 135
. . . . . . . . . . 0 4 0 0 0 . 0 59 50 25 45 1.1 78 0.3 260 1.9 132
1 0 0 . . . . . . . 0 4 0 0 0 . 0 . . . . . 12 0.7 17 0.9 139
0 0 0 . . . . . . . 4 8 5 1 0 . 0 38 33 5 31 0.6 64 0.6 107 2.8 130
. . . 0 3 0 1.01 6 0 0 4 99 0 0 0 . 0 52 136 11 98 0.5 35 0.6 58 1.3 134
. . . 0 1 3 1.01 5 0 0 4 12 0 0 . . 0 59 96 22 111 1.6 168 3.5 48 4.6 146
. . . 0 1 3 1.01 5 0 0 10 4 5 1 0 . 0 . . . . . . . . . .
. . . 2 0 2 1.02 6 0 0 6 2 0 0 0 . . . . . . . . . . . .
DCl RFI FEN CXRAB1 AB2 AB3 Ion Diur Tx Cr0cr1 cr2 cr3 cr4 cr5 cr6 cr7 cr14 cr21 cr28 Hd
. . . 2 DoxicyCeftri . Yes FurosYes 5 . . 8.6 8.5 . . . . . . Yes
91 8.8 6.7 4 DoxicyAzithrPipra Yes No No 7 3.3 4.5 4.2 4.9 4 3.2 2.8 1.9 . . Yes
97 1.1 0.9 0 DoxicyAzithrCeftri No No No 1 . 0.8 . 0.8 . . . . . . No
103 4.1 3.1 4 DoxicyAzithrMero Yes No Yes 5 5.2 6.7 3.7 3.6 3 4.1 4 . . . Yes
. . . 2 Azithr Merop. Yes FurosNo 5 3.9 . . . . . . . . . Yes
104 . . 0 DoxicyCeftri . No No No 1 . 0.7 . . . . . . . . No
105 1 0.7 0 DoxicyAzithrCeftri No No No 1 1.3 1.1 . . . . . . . . No
107 1.8 1.4 0 DoxicyCeftri . No No No . 1.1 . . . . . . . . . No
104 . . 0 DoxicyMerop. No FurosYes 4 . 6.1 . 6.7 . . 11 3.1 . . Yes
109 0.1 0.1 2 DoxicyAzithrPipra Yes No No 2 . 1.1 1 . . . . . . . No
104 . . 0 DoxicyAzithrPipra No No No 2 2.1 2.7 1.8 . 1 . . . . . No
117 9.5 6.5 4 DoxicyAzithr. No No No 4 3.8 2.5 . . . . . . . . No
102 2.6 1.9 0 DoxicyCeftri . No No No 1 . 1 . . . . . . . . No
96 2.1 1.5 4 DoxicyAzithrPipra No FurosNo 1 . . . . . 0.6 . . . . No
110 0.5 0.4 2 DoxicyAzithrPipra Yes FurosNo 1 0.7 0.7 0.8 0.6 . 0.6 . . . . No
. . . 0 DoxicyCeftri . Yes No No 1 0.6 0.6 0.6 . . . . . . . No
97 1.3 1 4 CifranClox . Yes No No 2 1.9 2.6 2.5 2.6 . 1.7 1.5 . . . No
86 . . 3 DoxicyMerop. Yes No No 2 . 1.9 . . . . . . . . Yes
104 5.9 4.7 5 Doxicy. . No No No 2 1.1 1 . . . . . . . . No
97 6.4 5.3 0 Doxicy. . No No No 1 . . . . 1 . . . . . No
114 0.7 0.4 0 DoxicyAzithr. Yes No No 1 0.8 0.7 0.8 0.7 . . . . . . No
110 3.4 2.5 5 DoxicyPipraT. No FurosNo 1 . . . 0.7 . . . . . . No
99 0.2 0.1 0 Gatiflo. . No No No 1 . . 0.8 . . . . . . . No
100 4.3 3.2 2 DoxicyCefap. No FurosNo 6 . 7.7 6.3 5.4 5 . . 9.2 . . Yes
108 6.1 4.4 2 DoxicyAzithrMero Yes No No 1 . 2.3 2.2 2.3 . . . . . . No
98 2.9 2.4 0 DoxicyAzithr. No No No 1 . 0.7 . . . . . . . . No
107 . . 5 DoxicyGatiflo. No No No 1 . 0.9 . . . . . . . . No
109 0 0 2 DoxicyAzithrMero Yes FurosYes 0 . 0.6 0.6 0.5 1 0.4 0.4 . . . No
107 1.3 1 4 DoxicyAzithr. Yes No No 1 1.1 1.1 0.9 0.8 1 . . . . . No
116 . . 4 DoxicyAzithrPipra Yes No Yes 2 3.7 2.8 . . . . . . . . Yes
106 0.7 0.5 4 DoxicyAzithrPipra No FurosNo 2 1.2 1 0.8 0.8 . . . . . . No
105 3.2 2.3 4 DoxicyAzithrPipra No No No 3 2.5 2.5 1.8 1.3 . . . . . . No
. . . 4 DoxicyAzithrMero Yes No Yes 5 . 5 4.7 5 5 6 2.1 . . . Yes
92 18 17 4 DoxicyMerop. Yes No No 7 6.6 5.1 . . . . . . . . No
102 3.1 2.3 5 DoxicyCeftri . No No No 1 . . 0.8 . . . . . . . No
83 0.2 0.1 5 None . . No FurosNo 1 . . . 0.8 . . . . . . No
. . . 4 DoxicyAzithrMero No No No 1 1.6 1.6 1 0.8 1 . . . . . No
107 1.6 1.2 0 DoxicyCeftri . No No No 1 2.2 . . . . . . . . . No
106 0.2 0.1 5 DoxicyAzithrPipra No No No 2 2.5 2.5 2.5 1.7 1 . . . . . No
105 1.5 1.2 5 DoxicyCeftri . No No No 2 . 1.5 1.2 . . 0.9 . . . . No
100 3.5 2.6 5 DoxicyPipraTMero Yes FurosYes 4 . 5 5.9 6.9 7 7.9 8.9 . . . No
108 19 10 5 DoxicyAzithrPipra Yes No Yes 5 . . . . . . . . . . No
107 21 17 0 DoxicyArtes . No No No 10 9.6 11 10 9.7 7 4.9 . . 1.9 1.5 No
113 2.1 1.5 4 Azithr PipraT. Yes No No 1 . 1 1 . . 0.7 . . . . No
110 0.1 0.1 0 DoxicyAzithrPipra No No Yes 1 1.2 1.4 1.4 1.2 1 1.1 0.8 . . . No
106 44 30 2 DoxicyMerop. Yes No Yes 2 2.2 3.6 3.9 4.1 . . . . . . No
92 7.1 5.5 4 DoxicyAzithrMero Yes No No 1 . 2.7 2.3 3.3 2 3.9 5 . . . Yes
93 . . 2 DoxicyPipraT. No No No 2 1.7 1 0.9 . . . . . . . No
97 0.5 0.5 0 Gatiflo. . No No No 1 . 1 . . . . . . . . No
87 9.4 7.4 4 DoxicyAzithrCifranYes No No 2 2.4 1.8 . . . . . . . . No
95 7.6 5.1 4 DoxicyPipraT. Yes No No 7 5.8 5.9 6.6 . . . . . . . No
109 1.1 0.8 4 DoxicyAzithrPipra Yes No No 1 1.2 1 . 0.8 . 0.8 . . . . No
102 1.9 1.4 0 DoxicyCeftri . No No No 1 . . . 1.2 . . . . . . No
109 4.2 3 0 None . . No No No 1 . . . 1.6 . . . . . . No
104 2 1.5 6 ArtesuClinda. No No No 1 . . . 0.7 . . . . . . No
. . . 5 DoxicyAzithrPipra Yes No No 3 . 1.5 . . 1 0.7 . . . . No
92 0.2 0.2 0 DoxicyGatiflo. No No No 1 . . 1.3 . . . . . . . No
96 0.3 0.3 5 DoxicyCeftri . No No No 1 . 0.8 . . . . . . . . No
105 2.1 1.5 0 Chloro. . No No No . . . 1.1 . . . . . . . No
108 4.7 3.5 5 ArtesuCeftri . No No No 3 2.5 1.6 1.1 . . . . . . . No
105 0.2 0.1 0 None . . No No No 1 0.9 . . . . . . . . . No
103 2.4 1.7 4 DoxicyAzithrCeftri No No No 2 1.8 1.6 . . . . . . . . No
101 1.7 1.3 0 DoxicyAzithrCeftri No No No 1 . . 0.9 . . . . . . . No
111 0.1 0.1 4 DoxicyAzithrMero No No Yes 1 1.4 1 0.8 0.7 . . . . . . No
101 20 16 5 DoxicyArtes Pipra No No No 8 8 6.6 6.9 4.2 4 3.2 2.6 . . . Yes
. 2.5 . 5 DoxicyArtes Ceftri No No No 3 2.7 1.8 . . 1 1.3 1.3 . . . No
. 1.4 . 0 DoxicyArtes . No No No 2 . 0.8 0.8 . . 0.8 . . . . No
. 1.8 . 5 ChloroArtes LumifNo No No 1 1.4 . . . . . . . . . No
106 7.6 5.7 0 DoxicyArtes Pipra No No No 1 . 0.7 . . . . . . . . No
. . . 0 DoxicyArtes Pipra Yes No Yes 1 1.4 1 . . . . . . . . No
. 1.3 . 5 DoxicyArtes Ceftri No No No 1 . 0.7 . . . . . . . . No
105 3.7 2.7 5 DoxicyDoxicPipra No No Yes 1 . 0.9 0.6 0.6 1 . . . . . No
100 . . 3 Azithr Ceftri . No No No 1 0.7 . . . . . . . . . No
. . . 2 DoxicyPipraT. No No No 5 4.5 3.1 2.1 . . . . . . . No
83 1.3 1 5 DoxicyCeftri . No FurosNo 1 . . 0.9 . . . . . . . No
. 0.2 . 2 DoxicyAzithrPipra No No No 1 . 1 . . . . . . . . No
101 0.9 0.7 0 DoxicyCeftri . No No No 1 . 1 . . 1 . . . . . No
97 18 14 0 PipraT. . No No No 12 . 5.8 5 3.4 2 1.9 . . . . Yes
102 . . 0 Gatiflo. . No No No 1 . . . . 1 . . . . . No
104 76 55 4 DoxicyAzithrPipra No No No 15 16 14 10 12 10 9.7 7.1 . . . Yes
86 2.5 1.9 0 DoxicyCeftri . No No No 1 . . 1.4 . . . . . . . No
100 1.8 1.4 0 Gatiflo. . No No No 1 . . 1.3 . . . . . . . No
97 2.4 1.9 5 DoxicyGatiflo. No No No 1 . 0.8 . . . . . . . . No
103 0.1 0.1 5 DoxicyAzithrCeftri No No No 1 . 1.6 . . . . . . . . No
. 0.4 0.3 5 Doxicy. . No No No 1 1 . . . . . . . . . No
98 4 3 4 DoxicyAzithr. Yes No No 1 0.8 0.8 . . . . . . . . No
106 2.5 2 0 DoxicyArtes . No No No 1 1.2 . . . . . . . . . No
99 0.6 0.5 0 Chloro. . No No No 1 0.7 . . . . . . . . . No
124 4.1 2.9 4 DoxicyAzithrPipra No No No 3 . 2 1.6 . 1 0.9 . . . . No
102 3.5 2.6 4 DoxicyAzithrPipra Yes No No 7 6.6 6.2 . . . . . . . . Yes
103 3.7 2.8 4 DoxicyAzithrMero Yes No Yes 8 . 4.9 2.4 2.1 2 1.3 1 1 . . No
97 5.2 4.3 0 DoxicyAzithrGatifl No No No 6 6 4.5 2.8 4.3 . . 3.3 . . . Yes
85 1.3 1 4 DoxicyArtes Pipra Yes No No 5 . . . . . . . . . . Yes
121 1.9 1.3 2 DoxicyAzithrPipra No No Yes 2 . 1.5 1.2 1.1 . . . . . . No
100 1 0.7 0 DoxicyAzithr. No No No 5 3.6 2.1 1.1 1 . . . . . . No
104 1.3 0.9 0 Doxicy. . No No No 2 1.4 . . . . . . . . . No
111 3.6 2.5 3 DoxicyAzithrCeftri Yes No No 1 0.9 . 0.8 . . . . . . . No
102 1.8 1.3 0 DoxicyDoxicCeftri No No Yes 1 . . . 1.1 . . . . . . No
101 . . 0 Doxicy. . No No No 1 . . . . . . . . . . No
107 2.7 2 0 DoxicyArtes Pipra Yes No No 2 1.1 1.2 . 1.2 . . . . . . No
92 1 0.7 5 DoxicyAzithr. Yes No Yes 3 3 . . . . . . . . . No
97 22 17 4 Merop. . Yes FurosNo 7 . . . . . . . . . . No
111 4.7 3.4 2 DoxicyAzithrPipra No No No 6 5.5 . . 3.5 3 2.3 1.6 . . . No
120 0.3 0.2 1 DoxicyAzithrPipra No No No 3 4 2.9 2 1.6 . 1.5 1.3 . . . No
93 11 9.2 4 DoxicyMerop. Yes FurosNo 5 5.2 5.2 6 7.2 8 8.8 6.8 . . . Yes
106 8.7 6.6 1 DoxicyArtes Pipra Yes FurosYes 1 . 1.6 2.5 3.1 3 3.5 3.1 1.6 . . No
108 32 22 2 DoxicyArtes Pipra No No Yes 9 . 8 6.2 7.6 5 5.2 7.5 . . . Yes
. . . 4 DoxicyAzithrPipra Yes No Yes 2 2 1.2 0.7 . . . . . . . No
102 4.3 3.2 1 DoxicyAzithr. No No No 1 0.9 0.6 0.6 . . . . . . . No
99 1.6 1.2 4 DoxicyAzithrMero No No No 3 2.9 1.6 0.9 . 1 0.6 . . . . No
90 20 14 4 DoxicyAzithrPipra Yes No Yes 4 4.5 4.1 6.1 6.5 8 9.4 9.5 . . . Yes
101 . . 4 DoxicyAzithrMero Yes No No 2 1.7 1.5 2.4 2.7 4 4.1 4.4 . . . No
98 17 12 4 DoxicyPipraT. Yes No Yes 3 4 4.6 4.5 2.7 . . . . . . No
98 0.6 0.5 5 DoxicyArtes Ceftri No No Yes 1 . 2.2 . . . . . . . . No
105 3.1 2.2 5 Doxicy. . No No No 1 . . . 1 . 0.9 . . . . No
88 2.9 2.3 0 DoxicyCeftri . No No No 2 . . . . 1 . . . . . No
88 1.8 1.3 0 DoxicyAzithrPipra Yes No Yes 2 1.3 1.4 2.7 . . . . . . . Yes
95 . . 0 Doxicy. . Yes FurosNo 1 . . . . . 1.2 1.3 . . . No
106 26 19 4 DoxicyAzithrMero Yes No Yes 4 5.1 2.5 2.5 4 . . . . . . Yes
92 2.1 1.9 0 DoxicyAzithrCeftri No No No 1 . . 0.9 . . . . . . . No
104 . . 5 DoxicyArtes Ceftri No No No 3 1.6 1.4 . . 1 . . . . . No
101 0.1 0.1 1 DoxicyAzithrCeftri No No Yes 1 1 1 0.8 . 1 . . . . . No
99 3.5 3.1 0 DoxicyAzithrCeftri No No No 1 . 0.8 . . . . . . . . No
101 . . 5 DoxicyPipraT. No No No 6 . . . 6.1 6 4.6 3.1 . . . No
108 3.5 3 5 DoxicyAzithr. No No No 1 1.3 0.9 . 0.7 1 . . . . . No
96 1.5 1.2 0 DoxicyCeftri . No No No 1 . 1 . . . . . . . . No
114 . . 2 DoxicyPipraT. Yes No No 2 1.7 . . . . . . . . . No
106 . . 4 DoxicyAzithrPipra Yes No No 2 2.5 . . . . . . . . . Yes
104 6.2 4.6 0 DoxicyArtes Pipra No No Yes 5 . 3.3 5.6 4.7 7 . . . . 4.5 Yes
107 0.3 0.2 2 DoxicyArtes Ceftri No No No 1 0.4 1 . 0.6 . . . . . . No
110 . . 0 None . . No FurosYes 1 0.7 . . . . . . . . . No
102 0.5 0.4 0 Doxicy. . No No No 2 1.7 0.4 . . . . . . . . No
99 1.6 1.2 1 ArtesuClindaLumifNo No Yes 1 0.8 0.9 0.9 0.8 1 0.7 . . . . No
116 5.8 4 4 DoxicyAzithr. Yes FurosYes 3 . 2.9 2.8 3 4 . . . . . Yes
. . . 4 DoxicyArtes . No No Yes 5 . 3.9 4.2 4.1 6 . . . . . Yes
. . . 4 Azithr PipraT. No No No 2 . 1.1 . . . . . . . . No
Hdn HD Dur Ind Fre Typ Acc Hep SurvRIFCRIFGRIFF RIFNARFARF ERIFEAR ARFNVellScLian0
1 Yes 0 Hyper IntemSLE FemoRigid 0 3 3 3 3 3 1 3 1 1 . .
1 Yes 0 MetabIntemReguFemoRigid 1 3 3 3 3 3 1 3 1 1 1 0.41
. No . . . . . . . 0 0 0 0 0 0 3 1 0 1 0.21
5 No 5 MetabIntemReguFemoSaline 1 3 3 3 3 3 1 3 1 1 1 0.48
1 Yes 0 MetabIntemSLE FemoSaline 0 3 3 3 3 3 1 . . 1 1 0.59
. No . . . . . . . 0 0 0 0 0 0 0 0 0 0.91 0.05
. No . . . . . . . 0 1 1 1 0 0 2 1 1 0.98 0.22
. No . . . . . . . 0 1 1 1 0 0 2 1 1 1 0.17
4 Yes 7 AnuriaIntemReguFemoSaline 1 3 3 3 3 3 1 3 1 1 0.99 0.18
. No . . . . . . . 1 1 1 1 1 1 3 1 1 1 0.4
. No . . . . . . . 3 3 3 3 3 1 3 1 1 1 0.54
. No . . . . . . . 3 3 3 3 3 1 3 1 1 1 0.62
. No . . . . . . . 0 0 0 0 0 0 0 0 0 1 0.24
. No . . . . . . . 0 0 0 0 0 0 1 1 0 1 0.29
. No . . . . . . . 0 0 0 0 0 0 2 1 0 0.8 0.16
. No . . . . . . . 1 1 1 1 1 1 . . 1 1 0.62
. Yes . . . . . . . 3 2 3 3 3 1 3 1 1 1 0.17
2 Yes 0 AnuriaIntemSLE FemoRigid 0 2 2 2 2 2 1 3 1 1 1 0.31
. No . . . . . . . 2 2 2 2 2 1 2 1 1 1 0.34
. No . . . . . . . 0 0 0 0 0 0 2 1 0 1 0.38
. No . . . . . . . 0 0 0 0 0 0 1 1 0 0.91 0.37
. No . . . . . . . 0 0 0 0 0 0 1 1 0 1 0.11
. No . . . . . . . 0 0 0 0 0 0 2 1 0 0.69 0.18
5 Yes 5 MetabIntemReguFemoRigid 1 3 3 3 3 3 1 3 1 1 0.94 0.15
. No . . . . . . . 3 2 3 3 3 1 3 1 1 1 0.43
. No . . . . . . . 0 0 0 0 0 0 2 1 0 1 0.26
. No . . . . . . . 0 0 0 0 0 0 1 1 0 0.86 0.27
. No . . . . . . . 0 0 0 0 0 0 2 1 0 1 0.62
. No . . . . . . . 0 0 0 0 0 0 0 0 0 1 0.52
3 Yes 1 Hyper IntemSLE FemoSaline 0 3 3 3 3 3 1 3 1 1 1 0.69
. No . . . . . . . 0 1 1 1 0 0 2 1 1 0.92 0.39
. No . . . . . . . 2 2 2 2 2 1 2 1 1 1 0.67
1 Yes 0 MetabIntemReguFemoSaline 0 3 3 3 3 3 1 . . 1 0.98 0.33
. No . . . . . . . 3 3 3 3 3 1 3 1 1 1 0.37
. No . . . . . . . 0 0 0 0 0 0 0 0 0 1 0.36
. No . . . . . . . 0 0 0 0 0 0 1 1 0 0.7 0.27
. No . . . . . . . 2 2 2 2 2 1 . . 1 1 0.68
. No . . . . . . . 2 2 2 2 2 1 3 1 1 0.98 0.13
. No . . . . . . . 2 2 2 2 2 1 3 1 1 1 0.5
. No . . . . . . . 1 1 1 1 1 1 2 1 1 0.93 0.38
. No . . . . . . . 3 3 3 3 3 1 . . 1 1 0.62
. No . . . . . . . 3 3 3 3 3 1 3 1 1 . .
. No . . . . . . . 3 3 3 3 3 1 3 1 1 0.99 0.36
. No . . . . . . . 0 0 0 0 0 0 2 1 0 0.98 0.58
. No . . . . . . . 1 1 1 1 1 1 3 1 1 1 0.58
. No . . . . . . . 3 3 3 3 3 1 3 1 1 . .
3 Yes 7 AnuriaIntemSLE FemoRigid 0 3 3 3 3 3 1 1 1 1 1 0.44
. No . . . . . . . 2 2 2 2 2 1 1 1 1 0.96 0.42
. No . . . . . . . 0 0 0 0 0 0 0 0 0 0.52 0.18
. No . . . . . . . 2 2 2 2 2 1 2 1 1 0.99 0.28
. No . . . . . . . 3 3 3 3 3 1 3 1 1 1 0.59
. No . . . . . . . 1 1 1 1 1 1 2 1 1 1 0.57
. No . . . . . . . 0 1 1 1 0 0 1 1 1 0.74 0.19
. No . . . . . . . 1 1 1 1 1 1 2 1 1 0.95 0.13
. No . . . . . . . 0 0 0 0 0 0 0 0 0 0.96 0.39
. No . . . . . . . 3 3 3 3 3 1 . . 1 1 0.76
. No . . . . . . . 1 1 1 1 1 1 2 1 1 1 0.3
. No . . . . . . . 0 0 0 0 0 0 1 1 0 1 0.37
. No . . . . . . . 0 0 0 0 0 0 2 1 0 0.9 0.22
. No . . . . . . . 3 2 3 3 3 1 2 1 1 1 0.27
. No . . . . . . . 0 0 0 0 0 0 0 0 0 0.84 0.17
. No . . . . . . . 2 2 2 2 2 1 2 1 1 1 0.49
. No . . . . . . . 0 1 1 1 0 0 2 1 1 1 0.17
. No . . . . . . . 1 2 2 2 1 1 3 1 1 1 0.67
2 Yes 2 Uremi DailyReguFemoRigid 1 3 3 3 3 3 1 3 1 1 0.96 0.32
. No . . . . . . . 3 3 3 3 3 1 2 1 1 1 0.25
. No . . . . . . . 0 1 1 1 0 0 0 0 1 0.91 0.3
. No . . . . . . . 0 0 0 0 0 0 1 1 0 0.84 0.18
. No . . . . . . . 0 0 0 0 0 0 0 0 0 0.96 0.32
. No . . . . . . . 0 1 1 1 0 0 0 0 1 0.98 0.43
. No . . . . . . . 0 0 0 0 0 0 1 1 0 1 0.44
. No . . . . . . . 0 0 0 0 0 0 1 1 0 1 0.39
. No . . . . . . . 1 1 1 1 1 1 . . 1 1 0.35
. No . . . . . . . 3 3 3 3 3 1 3 1 1 1 0.66
. No . . . . . . . 0 0 0 0 0 0 2 1 0 1 0.43
. No . . . . . . . 0 0 0 0 0 0 2 1 0 1 0.35
. No . . . . . . . 0 1 1 1 0 0 1 1 1 0.9 0.21
1 Yes 0 Uremi IntemReguFemoRigid 1 3 3 3 3 3 1 3 1 1 0.97 0.33
. No . . . . . . . 0 0 0 0 0 0 0 0 0 0.77 0.11
4 Yes 5 MetabIntemReguFemoRigid 1 3 3 3 3 3 1 3 1 1 0.97 0.48
. No . . . . . . . 0 1 1 1 0 0 2 1 1 0.97 0.24
. No . . . . . . . 0 1 1 1 0 0 1 1 1 0.91 0.1
. No . . . . . . . 0 0 0 0 0 0 1 1 0 1 0.4
. No . . . . . . . 2 2 2 2 2 1 2 1 1 1 0.33
. No . . . . . . . 0 0 0 0 0 0 2 1 0 0.99 0.24
. No . . . . . . . 0 1 1 1 0 0 2 1 1 1 0.59
. No . . . . . . . 0 0 0 0 0 0 1 1 0 0.73 0.18
. No . . . . . . . 0 0 0 0 0 0 0 0 0 1 0.51
. No . . . . . . . 2 2 2 2 2 1 2 1 1 1 0.63
2 Yes 1 MetabIntemReguFemoSaline 0 3 3 3 3 3 1 3 1 1 1 0.37
. No . . . . . . . 3 3 3 3 3 1 3 1 1 1 0.46
2 Yes 1 Hyper IntemReguIJV Saline 1 3 3 3 3 3 1 3 1 1 0.98 0.42
1 Yes 0 MetabDailySLE FemoSaline 0 3 3 3 3 3 1 0 0 1 1 0.36
. No . . . . . . . 2 2 2 2 2 1 3 1 1 0.99 0.24
. No . . . . . . . 3 3 3 3 3 1 3 1 1 1 0.37
. No . . . . . . . 1 1 1 1 1 1 2 1 1 0.99 0.34
. No . . . . . . . 0 1 1 1 0 0 2 1 1 1 0.27
. No . . . . . . . 0 0 0 0 0 0 0 0 0 0.69 0.19
. No . . . . . . . 1 1 1 1 1 1 1 1 1 0.99 0.32
. No . . . . . . . 1 1 1 1 1 1 1 1 1 1 0.39
. . . . . . . . . 3 3 3 3 3 1 3 1 1 1 0.56
. 3 . . . . . . . 3 3 3 3 3 1 3 1 1 1 0.45
. No . . . . . . . 3 3 3 3 3 1 3 1 1 1 0.33
. No . . . . . . . 3 3 3 3 3 1 3 1 1 1 0.74
7 Yes 12 Uremi IntemSLE FemoRigid 0 3 3 3 3 3 1 3 1 1 1 0.38
. No . . . . . . . 3 3 3 3 3 1 1 1 1 1 0.48
8 Yes 9 MetabIntemReguFemoSaline 0 3 3 3 3 3 1 3 1 1 1 0.65
. No . . . . . . . 2 2 2 2 2 1 . . 1 0.99 0.44
. No . . . . . . . 0 0 0 0 0 0 2 1 0 0.99 0.51
. No . . . . . . . 3 3 3 3 3 1 2 1 1 1 0.51
5 Yes 6 MetabIntemReguFemoSaline 0 3 3 3 3 3 1 3 1 1 1 0.68
. No . . . . . . . 3 3 3 3 3 1 3 1 1 . .
. No . . . . . . . 3 3 3 3 3 1 3 1 1 1 0.58
. No . . . . . . . 2 2 2 2 2 1 3 1 1 1 0.41
. No . . . . . . . 0 1 1 1 0 0 0 0 1 1 0.29
. No . . . . . . . 1 1 1 1 1 1 0 0 1 1 0.12
1 Yes 0 MetabIntemSLE FemoSaline 0 3 3 3 3 3 1 3 1 1 1 0.53
. No . . . . . . . 2 2 2 2 2 1 . . 1 . .
3 Yes 3 MetabIntemSLE FemoSaline 0 3 3 3 3 3 1 3 1 1 1 0.78
. No . . . . . . . 0 0 0 0 0 0 2 1 0 1 0.4
. No . . . . . . . 2 2 2 2 2 1 2 1 1 1 0.48
. No . . . . . . . 0 0 0 0 0 0 1 1 0 0.99 0.42
. No . . . . . . . 0 1 1 1 0 0 2 1 1 1 0.46
. No . . . . . . . 3 3 3 3 3 1 3 1 1 1 0.32
. No . . . . . . . 2 2 2 2 2 1 2 1 1 1 0.37
. No . . . . . . . 0 0 0 0 0 0 1 1 0 0.97 0.22
. No . . . . . . . 2 2 2 2 2 1 2 1 1 . .
1 Yes 0 MetabIntemSLE FemoSaline 0 3 2 3 3 3 1 2 1 1 1 0.76
3 Yes 3 MetabIntemReguFemoSaline 1 3 3 3 3 3 1 3 1 1 1 0.36
. No . . . . . . . 0 1 1 1 0 0 2 1 1 1 0.53
. No . . . . . . . 0 0 0 0 0 0 0 0 0 1 0.45
. No . . . . . . . 2 2 2 2 2 1 3 1 1 1 0.49
. No . . . . . . . 0 0 0 0 0 0 1 1 0 1 0.68
3 Yes 2 MetabIntemSLE FemoSaline 0 3 3 3 3 3 1 3 1 1 1 0.65
4 Yes 3 MetabIntemSLE FemoSaline 0 3 3 3 3 3 1 . . 1 1 0.79
. No . . . . . . . 1 2 2 2 1 1 . . 1 1 0.17
